Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage

Abstract

To provide a composition and a method for administering an oxytocin antagonist to a subject undergoing embryo implantation therapy so as to improve endometrial receptivity and reduce the likelihood of embryo implantation failure in the subject.SOLUTION: The present invention provides a pharmaceutical composition for use in a method that employs a compound represented by formula (II) to treat a subject undergoing embryo implantation therapy, in which one or more embryos are transplanted into the uterus of the subject, wherein the method comprises administering the compound to the subject in an amount of about 1,800 mg.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present disclosure relates to compositions and methods for administering an oxytocin receptor antagonist to a subject undergoing embryo transfer therapy to increase endometrial receptivity and reduce the likelihood of embryo implantation failure. [Background technology]

[0002] Despite recent advances in assisted reproductive technology, even more advanced treatments such as in vitro fertilization (IVF) followed by embryo transfer (IVF / ET) remain relatively uneffective overall, resulting in an average of approximately 30% live births per treatment cycle (Andersen et al., Human Reproduction 24:1267-1287 (2009)). Furthermore, successful embryo implantation rates tend to decrease with age. Many current treatment strategies to promote successful embryo transfer in subjects undergoing embryo transfer therapy have focused on suppressing uterine contractions prior to embryo transfer. Such treatments include the administration of beta-adrenergic receptor agonists and nonsteroidal anti-inflammatory drugs (NSAIDS), which have not been shown to provide sufficient clinical benefit (Bernabeu et al., Human Reproduction 21:364-368 (2006); Moon et al., Fertility and Sterility 82:816-820 (2004); and Tsirigotis et al., Human Reproduction 15:10 (2000)). For example, there remains a need for improved therapeutic procedures and administration regimens that can be used to promote successful embryo implantation by increasing endometrial receptivity at the time of embryo transfer in patients undergoing assisted reproductive technology procedures. Summary of the Invention

[0003] The present disclosure provides a method for administering an oxytocin receptor antagonist to a subject undergoing embryo transfer therapy, for example, to improve endometrial receptivity during embryo implantation, thereby reducing the likelihood of embryo implantation failure and miscarriage. Oxytocin receptor antagonists that can be used in conjunction with the compositions and methods described herein include substituted pyrrolidin-3-one oxime compounds, such as (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime. Further examples of oxytocin receptor antagonists that can be used in conjunction with the compositions and methods described herein include epelsiban, letosiban, barusiban, and atosiban, as well as derivatives and variants thereof. Using the compositions and methods described herein, such oxytocin antagonists can be administered to a subject before, during, or after embryo transfer to improve endometrial receptivity and reduce the likelihood of embryo implantation failure and miscarriage. The oxytocin antagonist may be administered to a subject in a single dose or multiple doses, such as doses of varying strength or repeated doses of the same strength. For example, the oxytocin antagonist may be administered to a subject undergoing embryo transfer in a single high dose or multiple low-strength doses to achieve a maximum plasma concentration of the oxytocin antagonist (e.g., about 1 μM to about 20 μM, such as a compound represented by Formula (I) or (II) as described herein). According to the methods of the present disclosure, an oxytocin receptor antagonist, such as those described herein, may be administered to a subject before, concurrently with, or after the intrauterine transfer of one or more embryos produced in vitro by, for example, in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment. The one or more embryos may be produced, for example, by fertilization of eggs derived from a subject undergoing embryo transfer treatment, or may be derived from a donor not undergoing embryo transfer treatment.

[0004] The present disclosure is based, in part, on the discovery of doses of oxytocin receptor antagonists, such as compounds of formula (I) (e.g., (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime), that are particularly effective in enhancing endometrial receptivity through multiple modes of action. In particular, it has now been discovered that doses of compounds of formula (I), such as (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, reduce uterine contractility and enhance blood flow to the endometrium. These effects provide important therapeutic benefits to patients undergoing embryo transfer therapy. Together, the reduced uterine contractility and enhanced endometrial perfusion caused by compounds of formula (I), such as (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, create an environment within the uterus that is favorable for successful embryo implantation. Without being limited by mechanism, these biological activities represent ways in which compounds of the present disclosure may reduce the likelihood of embryo implantation failure and miscarriage.

[0005] In a first aspect, the present disclosure provides a method for administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to a subject in an amount of about 1,500 mg to about 2,700 mg per dose. For example, the compound may be administered in an amount of about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,790 mg to about 1,810 mg per dose, about 1,791 mg to about 1,809 mg per dose, or about 1,792 mg to about 1,830 mg per dose. The compound may be administered to a subject in an amount of about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0006] In some embodiments, the compound is administered at a dose of about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,450 mg per dose, about 2,450 mg to about 2,460 mg per dose, about 2,460 mg to about 2,470 mg per dose, about 2,470 mg to about 2,480 mg per dose, about 2,480 mg to about 2,490 mg per dose, about 2,491 mg to about 2,492 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,50 ... The compound is administered to a subject in an amount of about 2,408 mg, about 2,393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0007] In some embodiments, the compound is administered in an amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg, 1,690 mg, 1,700 mg, 1,710 mg, 1,720 mg, 1,730 mg, 1,740 mg, 1,750 mg, 1,760 mg, 1,770 mg, 1,780 mg, 1,790 mg, 2,800 mg, 2,810 mg, 2,820 mg, 2,830 mg, 2,840 mg, 2,850 mg, 2,860 mg, 2,870 mg, 2,880 mg, 2,890 mg, 3,900 mg, 3,910 mg, 3,920 mg, 3,930 mg, 3,940 mg, 3,950 mg, 3,960 mg, 3,970 mg, 3,980 mg, 3,990 mg, 4,000 mg, 4,010 mg, 4,020 mg, 4,030 mg, 4,040 mg, 4,050 mg, 4,060 mg, 4,070 mg, 4,080 mg, 4,090 mg, 5,100 mg, 5,110 mg, 5 670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1, 770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,8 70mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,9 70mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,07 The compound is administered to a subject in an amount of 0 mg, 2,080 mg, 2,090 mg, or 2,100 mg, for example, in an amount of about 1,800 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0008] In some embodiments, the compound is administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 300 mg, 301 mg, 302 mg, 303 mg, 304 mg, 305 mg, 306 mg, 307 mg, 308 mg, 309 mg, 310 mg, 311 mg, 312 mg, 313 mg, 314 mg, 315 mg, 316 mg, 317 mg, 318 mg, 319 mg, 320 mg, 321 mg, 322 mg, 323 mg, 324 mg, 325 mg, 326 mg, 327 mg, 328 mg, 329 mg, 330 mg, 331 mg, 332 mg, 333 mg, 334 mg, 335 mg, 336 mg, 337 mg, 338 mg, 339 mg, 340 mg, 341 mg, 342 mg, 343 mg, 3 270mg, 2,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2, 370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,4 70mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,5 70mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,67 The compound is administered to a subject in an amount of 0 mg, 2,680 mg, 2,690 mg, or 2,700 mg, for example, in an amount of about 2,400 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0009] In some embodiments, the compound is administered in an amount of about 1,600 mg to about 2,600 mg per dose, e.g., about 1,610 mg to about 2,590 mg per dose, about 1,620 mg to about 2,580 mg per dose, about 1,630 mg to about 2,570 mg per dose, about 1,640 mg to about 2,560 mg per dose, about 1,650 mg to about 2,550 mg per dose, about 1,660 mg to about 2,540 mg per dose, about 1,670 mg to about 2,530 mg per dose, about 1,680 mg to about 2,520 mg per dose, about 1,690 mg to about 2,5 ... 10 mg, about 1,700 mg to about 2,500 mg per dose, about 1,710 mg to about 2,490 mg per dose, about 1,720 mg to about 2,480 mg per dose, about 1,730 mg to about 2,470 mg per dose, about 1,740 mg to about 2,460 mg per dose, about 1,750 mg to about 2,450 mg per dose, about 1,760 mg to about 2,440 mg per dose, about 1,770 mg to about 2,430 mg per dose, about 1,780 mg to about 2,420 mg per dose, about 1,790 mg to about 2,410 mg per dose, about 1,800 mg to about 2,500 mg per dose 2,400 mg, about 1,810 mg to about 2,390 mg per dose, about 1,820 mg to about 2,380 mg per dose, about 1,830 mg to about 2,370 mg per dose, about 1,840 mg to about 2,360 mg per dose, about 1,850 mg to about 2,350 mg per dose, about 1,860 mg to about 2,340 mg per dose, about 1,870 mg to about 2,330 mg per dose, about 1,880 mg to about 2,320 mg per dose, about 1,890 mg to about 2,310 mg per dose, about 1,900 mg to about 2,300 mg per dose, about 1,910 mg to about 2,360 mg per dose mg to about 2,290 mg per dose, about 1,920 mg to about 2,280 mg per dose, about 1,930 mg to about 2,270 mg per dose, about 1,940 mg to about 2,260 mg per dose, about 1,950 mg to about 2,250 mg per dose, about 1,960 mg to about 2,240 mg per dose, about 1,970 mg to about 2,230 mg per dose, about 1,980 mg to about 2,220 mg per dose, about 1,990 mg to about 2,210 mg per dose, about 2,000 mg to about 2,200 mg per dose, about 2,010 mg to about 2,190 mg per dose, about 2,The compound is administered to a subject in an amount of about 0.020 mg to about 2,180 mg per dose, about 2,030 mg to about 2,170 mg per dose, about 2,040 mg to about 2,160 mg per dose, about 2,050 mg to about 2,150 mg per dose, about 2,060 mg to about 2,140 mg per dose, about 2,070 mg to about 2,130 mg per dose, about 2,080 mg to about 2,120 mg per dose, or about 2,090 mg to about 2,110 mg per dose, for example, about 2,100 mg per dose, for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0010] In another aspect, the present disclosure provides a method for administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to the subject in one or more doses (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling from about 1,500 mg to about 2,700 mg. For example, the compound may be administered in a total amount of about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,810 mg, about 1,815 mg to about 1,820 mg, about 1,825 mg to about 1,830 mg, about 1,835 mg to about 1,840 mg, about 1,845 mg to about 1,850 mg, about 1,850 mg to about 1,860 mg, about 1,865 mg to about 1,870 mg, about 1,875 mg to about 1,880 mg, about 1,885 mg to about 1,890 mg, about 1,891 mg to about 1,892 mg, about 1,893 mg to about 1,894 mg, about 1,895 mg to about 2,000 mg, about 1,896 mg to about 2,000 mg, about 1,897 mg to about 2,000 mg, about 1,898 mg to about 2 The compound may be administered to a subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0011] In some embodiments, the compound is administered in a total amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 2,406 mg, about 2,395 mg, about 2,405 mg, about 2,396 mg, about 2,404 mg, about 2,397 mg, about 2,403 mg, about 2,398 mg, about 2,402 mg, or about 2,399 mg, about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0012] In some embodiments, the compound is administered in a total amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg g, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,7 90mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or 2,100mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, in an amount of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0013] In some embodiments, the compound is administered in a total amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg g, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,3 90mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690mg, or 2,700mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0014] In some embodiments, the compound is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,600 mg to about 2,600 mg, for example, a total of about 1,610 mg to about 2,590 mg, about 1,620 mg to about 2,580 mg, about 1,630 mg to about 2,570 mg, about 1,640 mg to about 2,560 mg, about 1,650 mg to about 2,550 mg, about 1,660 mg to about 2,540 mg, about 1,670 mg to about 2,530 mg, about 1,680 mg to about 2,520 mg, about 1,690 mg to about 2,510mg, about 1,700mg to about 2,500mg, about 1,710mg to about 2,490mg, about 1,720mg to about 2,480mg, about 1,730mg to about 2,470mg, about 1,740mg to about 2,460mg, about 1,750mg to about 2,450mg, about 1,760m g~2,440mg, 1,770mg~2,430mg, 1,780mg~2,420mg, 1,790mg~2,410mg, 1,800mg~2,400mg, 1,810mg~2,390mg, 1,820mg~2,380mg, 1,8 30mg to about 2,370mg, about 1,840mg to about 2,360mg, about 1,850mg to about 2,350mg, about 1,860mg to about 2,340mg, about 1,870mg to about 2,330mg, about 1,880mg to about 2,320mg, about 1,890mg to about 2,310mg, Approximately 1,900mg to approximately 2,300mg, approximately 1,910mg to approximately 2,290mg, approximately 1,920mg to approximately 2,280mg, approximately 1,930mg to approximately 2,270mg, approximately 1,940mg to approximately 2,260mg, approximately 1,950mg to approximately 2,250mg, approximately 1,960mg to approximately 2,240 mg, about 1,970 mg to about 2,230 mg, about 1,980 mg to about 2,220 mg, about 1,990 mg to about 2,210 mg, about 2,000 mg to about 2,200 mg, about 2,010 mg to about 2,190 mg, about 2,020 mg to about 2,180 mg, about 2,030 mg to about 2,170 mg, about 2,040 mg to about 2,160 mg, about 2,050 mg to about 2,150 mg, about 2,060 mg to about 2,140 mg, about 2,070 mg to about 2,130 mg, about 2,080 mg to about 2,120 mg, or about 2,090 mg to about 2,110 mg, for example, about 2,The compound is administered to the subject in one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0015] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0016] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0017] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0018] In a further aspect, the present disclosure provides a method for administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to the subject (eg, on the day of embryo transfer therapy) in a single dose of about 1,500 mg to about 2,700 mg. For example, the compound may be administered in an amount of about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, or about 1,793 mg to about 1,807 mg. The compound may be administered to a subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0019] In some embodiments, the compound is administered in an amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,419 mg, The compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0020] In some embodiments, the compound is administered in an amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1 ,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1, 780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,88 0mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980 mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg , 2,090 mg, or 2,100 mg in a single dose (e.g., on the day of embryo transfer therapy), for example, in an amount of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0021] In some embodiments, the compound is administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 2,400 mg, 2,410 mg, 2,420 mg, 2,430 mg, 2,440 mg, 2,450 mg, 2,460 mg, 2,470 mg, 2,480 mg, 2,490 mg, 300 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 3450 mg, 3460 mg, 3470 mg, 350 mg, 350 mg, 350 mg, 360 mg, 375 mg, 380 mg, 385 mg, 386 mg, 387 mg, 388 mg, 389 mg, 390 mg, 391 mg, 392 mg, 393 mg, 394 mg, 395 mg, 396 mg, 397 mg, 398 mg, 399 mg, 400 mg, 401 mg ,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2, 380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,48 0mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580 mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg , 2,690 mg, or 2,700 mg in a single dose (e.g., on the day of embryo transfer therapy), for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0022] In some embodiments, the compound is administered in a single dose of about 1,600 mg to about 2,600 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,610 mg to about 2,590 mg, about 1,620 mg to about 2,580 mg, about 1,630 mg to about 2,570 mg, about 1,640 mg to about 2,560 mg, about 1,650 mg to about 2,550 mg, about 1,660 mg to about 2,540 mg, about 1,670 mg to about 2,530 mg, about 1,680 mg to about 2,520 mg, about 1,690 mg to about 2,510 mg, or about 1,700 mg to about 2,500 mg , about 1,710mg to about 2,490mg, about 1,720mg to about 2,480mg, about 1,730mg to about 2,470mg, about 1,740mg to about 2,460mg, about 1,750mg to about 2,450mg, about 1,760mg to about 2,440mg, about 1,770mg Approximately 2,430mg, approximately 1,780mg to approximately 2,420mg, approximately 1,790mg to approximately 2,410mg, approximately 1,800mg to approximately 2,400mg, approximately 1,810mg to approximately 2,390mg, approximately 1,820mg to approximately 2,380mg, approximately 1,830mg to approximately 2,370mg, approximately 1 ,840mg~about 2,360mg,about 1,850mg~about 2,350mg,about 1,860mg~about 2,340mg,about 1,870mg~about 2,330mg,about 1,880mg~about 2,320mg,about 1,890mg~about 2,310mg,about 1,900mg~about 2, 300mg, about 1,910mg to about 2,290mg, about 1,920mg to about 2,280mg, about 1,930mg to about 2,270mg, about 1,940mg to about 2,260mg, about 1,950mg to about 2,250mg, about 1,960mg to about 2,240mg, about 1,97 0 mg to about 2,230 mg, about 1,980 mg to about 2,220 mg, about 1,990 mg to about 2,210 mg, about 2,000 mg to about 2,200 mg, about 2,010 mg to about 2,190 mg, about 2,020 mg to about 2,180 mg, about 2,030 mg to about 2,170 mg, about 2,040 mg to about 2,160 mg, about 2,050 mg to about 2,150 mg, about 2,060 mg to about 2,140 mg, about 2,070 mg to about 2,130 mg, about 2,080 mg to about 2,120 mg, or about 2,090 mg to about 2,110 mg, for example, about 2,A single dose of 100 mg is administered to the subject (e.g., on the day of embryo transfer therapy), and the compound is, for example, (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0023] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0024] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0025] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0026] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0027] In some embodiments of any of the above aspects of the present disclosure, an oxytocin antagonist is administered to a subject prior to transfer of one or more embryos (e.g., one, two, three, or more embryos) to the subject's uterus. In some embodiments, the administration reduces the likelihood of embryo implantation failure and / or miscarriage.

[0028] In another aspect, the disclosure provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject administers a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to a subject in an amount of about 1,500 mg to about 2,700 mg per dose. For example, the compound may be administered in an amount of about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,790 mg to about 1,810 mg per dose, about 1,791 mg to about 1,809 mg per dose, or about 1,792 mg to about 1,800 mg per dose. The compound may be administered to a subject in an amount of about 8 mg, about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0029] In some embodiments, the compound is administered at a dose of about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,450 mg per dose, about 2,450 mg to about 2,460 mg per dose, about 2,460 mg to about 2,470 mg per dose, about 2,470 mg to about 2,480 mg per dose, about 2,480 mg to about 2,490 mg per dose, about 2,491 mg to about 2,492 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,50 ... The compound is administered to a subject in an amount of about 2,408 mg, about 2,393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0030] In some embodiments, the compound is administered in an amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg, 1,690 mg, 1,700 mg, 1,710 mg, 1,720 mg, 1,730 mg, 1,740 mg, 1,750 mg, 1,760 mg, 1,770 mg, 1,780 mg, 1,790 mg, 2,800 mg, 2,810 mg, 2,820 mg, 2,830 mg, 2,840 mg, 2,850 mg, 2,860 mg, 2,870 mg, 2,880 mg, 2,890 mg, 3,900 mg, 3,910 mg, 3,920 mg, 3,930 mg, 3,940 mg, 3,950 mg, 3,960 mg, 3,970 mg, 3,980 mg, 3,990 mg, 4,000 mg, 4,010 mg, 4,020 mg, 4,030 mg, 4,040 mg, 4,050 mg, 4,060 mg, 4,070 mg, 4,080 mg, 4,090 mg, 5,100 mg, 5,110 mg, 5 670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1, 770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,8 70mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,9 70mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,07 The compound is administered to a subject in an amount of 0 mg, 2,080 mg, 2,090 mg, or 2,100 mg, for example, in an amount of about 1,800 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0031] In some embodiments, the compound is administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 300 mg, 301 mg, 302 mg, 303 mg, 304 mg, 305 mg, 306 mg, 307 mg, 308 mg, 309 mg, 310 mg, 311 mg, 312 mg, 313 mg, 314 mg, 315 mg, 316 mg, 317 mg, 318 mg, 319 mg, 320 mg, 321 mg, 322 mg, 323 mg, 324 mg, 325 mg, 326 mg, 327 mg, 328 mg, 329 mg, 330 mg, 331 mg, 332 mg, 333 mg, 334 mg, 335 mg, 336 mg, 337 mg, 338 mg, 339 mg, 340 mg, 341 mg, 342 mg, 343 mg, 3 270mg, 2,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2, 370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,4 70mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,5 70mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,67 The compound is administered to a subject in an amount of 0 mg, 2,680 mg, 2,690 mg, or 2,700 mg, for example, in an amount of about 2,400 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0032] In some embodiments, the compound is administered in an amount of about 1,600 mg to about 2,600 mg per dose, e.g., about 1,610 mg to about 2,590 mg per dose, about 1,620 mg to about 2,580 mg per dose, about 1,630 mg to about 2,570 mg per dose, about 1,640 mg to about 2,560 mg per dose, about 1,650 mg to about 2,550 mg per dose, about 1,660 mg to about 2,540 mg per dose, about 1,670 mg to about 2,530 mg per dose, about 1,680 mg to about 2,520 mg per dose, about 1,690 mg to about 2,5 ... 10 mg, about 1,700 mg to about 2,500 mg per dose, about 1,710 mg to about 2,490 mg per dose, about 1,720 mg to about 2,480 mg per dose, about 1,730 mg to about 2,470 mg per dose, about 1,740 mg to about 2,460 mg per dose, about 1,750 mg to about 2,450 mg per dose, about 1,760 mg to about 2,440 mg per dose, about 1,770 mg to about 2,430 mg per dose, about 1,780 mg to about 2,420 mg per dose, about 1,790 mg to about 2,410 mg per dose, about 1,800 mg to about 2,500 mg per dose 2,400 mg, about 1,810 mg to about 2,390 mg per dose, about 1,820 mg to about 2,380 mg per dose, about 1,830 mg to about 2,370 mg per dose, about 1,840 mg to about 2,360 mg per dose, about 1,850 mg to about 2,350 mg per dose, about 1,860 mg to about 2,340 mg per dose, about 1,870 mg to about 2,330 mg per dose, about 1,880 mg to about 2,320 mg per dose, about 1,890 mg to about 2,310 mg per dose, about 1,900 mg to about 2,300 mg per dose, about 1,910 mg to about 2,360 mg per dose mg to about 2,290 mg per dose, about 1,920 mg to about 2,280 mg per dose, about 1,930 mg to about 2,270 mg per dose, about 1,940 mg to about 2,260 mg per dose, about 1,950 mg to about 2,250 mg per dose, about 1,960 mg to about 2,240 mg per dose, about 1,970 mg to about 2,230 mg per dose, about 1,980 mg to about 2,220 mg per dose, about 1,990 mg to about 2,210 mg per dose, about 2,000 mg to about 2,200 mg per dose, about 2,010 mg to about 2,190 mg per dose, about 2,The compound is administered to a subject in an amount of about 0.20 mg to about 2,180 mg per dose, about 2,030 mg to about 2,170 mg per dose, about 2,040 mg to about 2,160 mg per dose, about 2,050 mg to about 2,150 mg per dose, about 2,060 mg to about 2,140 mg per dose, about 2,070 mg to about 2,130 mg per dose, about 2,080 mg to about 2,120 mg per dose, about 2,090 mg to about 2,110 mg per dose, for example, about 2,100 mg per dose, for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0033] In another aspect, the disclosure provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject administers a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to the subject in one or more doses (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling from about 1,500 mg to about 2,700 mg. For example, the compound may be administered in a total amount of about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,810 mg, about 1,815 mg to about 1,820 mg, about 1,825 mg to about 1,830 mg, about 1,835 mg to about 1,840 mg, about 1,845 mg to about 1,850 mg, about 1,850 mg to about 1,860 mg, about 1,865 mg to about 1,870 mg, about 1,875 mg to about 1,880 mg, about 1,885 mg to about 1,890 mg, about 1,891 mg to about 1,892 mg, about 1,893 mg to about 1,894 mg, about 1,895 mg to about 2,000 mg, about 1,896 mg to about 2,000 mg, about 1,897 mg to about 2,000 mg, about 1,898 mg to about 2 The compound may be administered to a subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0034] In some embodiments, the compound is administered in a total amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 2,406 mg, about 2,395 mg, about 2,405 mg, about 2,396 mg, about 2,404 mg, about 2,397 mg, about 2,403 mg, about 2,398 mg, about 2,402 mg, or about 2,399 mg, about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0035] In some embodiments, the compound is administered in a total amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg g, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,7 90mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or 2,100mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, in an amount of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0036] In some embodiments, the compound is administered in a total amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg g, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,3 90mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690mg, or 2,700mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0037] In some embodiments, the compound is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,600 mg to about 2,600 mg, for example, a total of about 1,610 mg to about 2,590 mg, about 1,620 mg to about 2,580 mg, about 1,630 mg to about 2,570 mg, about 1,640 mg to about 2,560 mg, about 1,650 mg to about 2,550 mg, about 1,660 mg to about 2,540 mg, about 1,670 mg to about 2,530 mg, about 1,680 mg to about 2,520 mg, about 1,690 mg to about 2,510mg, about 1,700mg to about 2,500mg, about 1,710mg to about 2,490mg, about 1,720mg to about 2,480mg, about 1,730mg to about 2,470mg, about 1,740mg to about 2,460mg, about 1,750mg to about 2,450mg, about 1,760m g~2,440mg, 1,770mg~2,430mg, 1,780mg~2,420mg, 1,790mg~2,410mg, 1,800mg~2,400mg, 1,810mg~2,390mg, 1,820mg~2,380mg, 1,8 30mg to about 2,370mg, about 1,840mg to about 2,360mg, about 1,850mg to about 2,350mg, about 1,860mg to about 2,340mg, about 1,870mg to about 2,330mg, about 1,880mg to about 2,320mg, about 1,890mg to about 2,310mg, Approximately 1,900mg to approximately 2,300mg, approximately 1,910mg to approximately 2,290mg, approximately 1,920mg to approximately 2,280mg, approximately 1,930mg to approximately 2,270mg, approximately 1,940mg to approximately 2,260mg, approximately 1,950mg to approximately 2,250mg, approximately 1,960mg to approximately 2,240 mg, about 1,970 mg to about 2,230 mg, about 1,980 mg to about 2,220 mg, about 1,990 mg to about 2,210 mg, about 2,000 mg to about 2,200 mg, about 2,010 mg to about 2,190 mg, about 2,020 mg to about 2,180 mg, about 2,030 mg to about 2,170 mg, about 2,040 mg to about 2,160 mg, about 2,050 mg to about 2,150 mg, about 2,060 mg to about 2,140 mg, about 2,070 mg to about 2,130 mg, about 2,080 mg to about 2,120 mg, or about 2,090 mg to about 2,110 mg, for example, about 2,The compound is administered to the subject in one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0038] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0039] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0040] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0041] In a further aspect, the present disclosure provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject administers a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,500 mg to about 2,700 mg. For example, the compound may be administered in doses of about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, or about 1,794 mg. The compound may be administered to a subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,806 mg, about 1,795 mg, about 1,805 mg, about 1,796 mg, about 1,804 mg, about 1,797 mg, about 1,803 mg, about 1,798 mg, about 1,802 mg, or about 1,799 mg, about 1,801 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II):

[0042] In some embodiments, the compound is administered in an amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,419 mg, The compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0043] In some embodiments, the compound is administered in an amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1 ,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1, 780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,88 0mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980 mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg , 2,090 mg, or 2,100 mg in a single dose (e.g., on the day of embryo transfer therapy), for example, in an amount of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0044] In some embodiments, the compound is administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 2,400 mg, 2,410 mg, 2,420 mg, 2,430 mg, 2,440 mg, 2,450 mg, 2,460 mg, 2,470 mg, 2,480 mg, 2,490 mg, 300 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 3450 mg, 3460 mg, 3470 mg, 350 mg, 350 mg, 350 mg, 360 mg, 375 mg, 380 mg, 385 mg, 386 mg, 387 mg, 388 mg, 389 mg, 390 mg, 391 mg, 392 mg, 393 mg, 394 mg, 395 mg, 396 mg, 397 mg, 398 mg, 399 mg, 400 mg, 401 mg ,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2, 380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,48 0mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580 mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg , 2,690 mg, or 2,700 mg in a single dose (e.g., on the day of embryo transfer therapy), for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0045] In some embodiments, the compound is administered in a single dose of about 1,600 mg to about 2,600 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,610 mg to about 2,590 mg, about 1,620 mg to about 2,580 mg, about 1,630 mg to about 2,570 mg, about 1,640 mg to about 2,560 mg, about 1,650 mg to about 2,550 mg, about 1,660 mg to about 2,540 mg, about 1,670 mg to about 2,530 mg, about 1,680 mg to about 2,520 mg, about 1,690 mg to about 2,510 mg, or about 1,700 mg to about 2,500 mg , about 1,710mg to about 2,490mg, about 1,720mg to about 2,480mg, about 1,730mg to about 2,470mg, about 1,740mg to about 2,460mg, about 1,750mg to about 2,450mg, about 1,760mg to about 2,440mg, about 1,770mg Approximately 2,430mg, approximately 1,780mg to approximately 2,420mg, approximately 1,790mg to approximately 2,410mg, approximately 1,800mg to approximately 2,400mg, approximately 1,810mg to approximately 2,390mg, approximately 1,820mg to approximately 2,380mg, approximately 1,830mg to approximately 2,370mg, approximately 1 ,840mg~about 2,360mg,about 1,850mg~about 2,350mg,about 1,860mg~about 2,340mg,about 1,870mg~about 2,330mg,about 1,880mg~about 2,320mg,about 1,890mg~about 2,310mg,about 1,900mg~about 2, 300mg, about 1,910mg to about 2,290mg, about 1,920mg to about 2,280mg, about 1,930mg to about 2,270mg, about 1,940mg to about 2,260mg, about 1,950mg to about 2,250mg, about 1,960mg to about 2,240mg, about 1,97 0 mg to about 2,230 mg, about 1,980 mg to about 2,220 mg, about 1,990 mg to about 2,210 mg, about 2,000 mg to about 2,200 mg, about 2,010 mg to about 2,190 mg, about 2,020 mg to about 2,180 mg, about 2,030 mg to about 2,170 mg, about 2,040 mg to about 2,160 mg, about 2,050 mg to about 2,150 mg, about 2,060 mg to about 2,140 mg, about 2,070 mg to about 2,130 mg, about 2,080 mg to about 2,120 mg, or about 2,090 mg to about 2,110 mg, for example, about 2,A single dose of 100 mg is administered to the subject (e.g., on the day of embryo transfer therapy), and the compound is, for example, (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0046] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0047] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0048] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0049] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0050] In some embodiments of any of the above aspects of the present disclosure, administration of the oxytocin antagonist reduces the likelihood of embryo implantation failure and / or miscarriage.

[0051] In a further aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered in an amount of about 1,500 mg to about 2,700 mg per dose (e.g., about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,840 mg to about 1,850 mg per dose, about 1,850 mg to about 1,860 mg per dose, about 1,870 mg to about 1,880 mg per dose, about 1,890 mg to about 2,920 mg per dose, about 1,940 mg to about 2,950 mg per dose, about 1,960 mg to about 2,970 mg per dose, about 1,980 mg to about 2,990 mg per dose, about 1,990 mg to about 2,990 mg per dose, about 2,000 mg to about 2,0 ... 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg per dose, about 1,792 mg to about 1,808 mg per dose, about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose, for example about 1,500 mg per dose, 1,666 0mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820 mg, 1,830 mg, 1,840 mg, 1,850 mg, 1,860 mg, 1,870 mg, 1,880 mg, 1,890 mg, 1,900 mg, 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg, e.g., about 1,000 mg per dose.In an amount of 800 mg, or about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,408 mg per dose, about 2,410 mg to about 2,420 ... 393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose, for example, about 2,400 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), and b. A method of treating a subject undergoing embryo transfer therapy by administering an oxytocin antagonist followed by transfer of one or more embryos (e.g., one, two, three, or more embryos) to the uterus of the subject is provided.

[0052] In another aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses) totaling about 1,500 mg to about 2,700 mg (e.g., totaling about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg). , about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, a total of 1,500 mg. 00mg, 1,510mg, 1,520mg, 1,530mg, 1,540mg, 1,550mg, 1,560mg, 1,570mg, 1,580mg, 1,590mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,6 50mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,80 0mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or 2,In one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses of about 1,800 mg total (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), or in a total of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg , about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 7 , 10 or more doses), for example, a total of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530 mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690 mg, or 2,700 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime) represented by Formula (II)); b. A method of treating a subject undergoing embryo transfer therapy by administering an oxytocin antagonist followed by transfer of one or more embryos (e.g., one, two, three, or more embryos) to the uterus of the subject is provided.

[0053] In a further aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered (e.g., on the day of embryo transfer therapy) in a single dose of about 1,500 mg to about 2,700 mg (e.g., about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,810 mg to about 1,820 mg, about 1,830 mg to about 1,840 mg, about 1,850 mg to about 1,850 mg, about 1,860 mg to about 1,870 mg, about 1,880 mg to about 1,890 mg, about 1,891 mg to about 2,920 mg, about 1,892 mg to about 2,930 mg, about 1,893 mg to about 2,940 mg, about 1,894 mg to about 2,950 mg, about 1,895 mg to about 2,960 mg, about 1,895 mg to about 2,970 mg, about 1,895 mg to about 2,980 mg, about 1,895 mg to about 2,995 mg, about 2,995 mg to about 3,000 mg, about 2,000 mg to about 3,0 A single dose of 792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,650mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,75 0mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, In a single dose of 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg (e.g., on the day of embryo transfer therapy), for example, in a single dose of about 1,800 mg (e.g., on the day of embryo transfer therapy), or about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,700 mg650mg, about 2,200mg to about 2,600mg, about 2,250mg to about 2,550mg, about 2,300mg to about 2,500mg, about 2,350mg to about 2,450mg, about 2,360mg to about 2,440mg, about 2,370mg to about 2,430mg, about 2,380mg Approximately 2,420mg, approximately 2,390mg to approximately 2,410mg, approximately 2,391mg to approximately 2,409mg, approximately 2,392mg to approximately 2,408mg, approximately 2,393mg to approximately 2,407mg, approximately 2,394mg to approximately 2,406mg, approximately 2,395mg to approximately 2,405mg, approximately 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., on the day of embryo transfer therapy), e.g., about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,4 40mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590m g, 2,600 mg, 2,610 mg, 2,620 mg, 2,630 mg, 2,640 mg, 2,650 mg, 2,660 mg, 2,670 mg, 2,680 mg, 2,690 mg, or 2,700 mg (e.g., on the day of embryo transfer therapy), for example, in an amount of about 2,400 mg to a subject (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)); b. A method of treating a subject undergoing embryo transfer therapy by administering an oxytocin antagonist followed by transfer of one or more embryos (e.g., one, two, three, or more embryos) to the uterus of the subject is provided.

[0054] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0055] In some embodiments of any of the above aspects of the present disclosure, the administration reduces the likelihood of embryo implantation failure and / or miscarriage.

[0056] In some embodiments of any of the above aspects of the present disclosure, the oxytocin antagonist is administered to the subject about 1 hour to about 24 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 1 hour to about 12 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 12 hours to about 24 hours prior to transfer of one or more embryos into the subject.

[0057] In some embodiments of any of the above aspects of the present disclosure, the oxytocin antagonist is administered to the subject about 1 hour to about 10 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 1 hour to about 9 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 1 hour to about 8 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 1 hour to about 7 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 1 hour to about 6 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 1 hour to about 5 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 1 hour to about 4 hours prior to transfer of one or more embryos into the subject.

[0058] In some embodiments of any of the above aspects of the present disclosure, the oxytocin antagonist is administered to the subject about 2 hours to about 6 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 3 hours to about 5 hours prior to transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours or more prior to transfer of one or more embryos into the subject.

[0059] In some embodiments of any of the above aspects of the present disclosure, the oxytocin antagonist is administered to the subject about 4 hours prior to transfer of the one or more embryos to the subject.

[0060] In some embodiments of any of the above aspects of the present disclosure, the oxytocin antagonist is administered to the subject prior to embryo transfer in a single dose.

[0061] In some embodiments of any of the above aspects of the disclosure, the oxytocin antagonist is administered to the subject prior to embryo transfer (i.e., prior to transfer of one or more embryos into the subject's uterus) in multiple doses (e.g., multiple periodic doses), such as 1 to 20 doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer prior to embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject at 1 to 20 doses every 24 hours prior to embryo transfer, such as 1 dose every 24 hours, 2 doses every 24 hours, 3 doses every 24 hours, 4 doses every 24 hours, 5 doses every 24 hours, 6 doses every 24 hours, 7 doses every 24 hours, 8 doses every 24 hours, 9 doses every 24 hours, 10 doses every 24 hours, 11 doses every 24 hours, 12 doses every 24 hours, 13 doses every 24 hours, 14 doses every 24 hours, 15 doses every 24 hours, 16 doses every 24 hours, 17 doses every 24 hours, 18 doses every 24 hours, 19 doses every 24 hours, or 20 doses every 24 hours. In some embodiments, the oxytocin antagonist is administered to the subject at more than 20 doses every 24 hours prior to embryo transfer.

[0062] For example, in some embodiments, the oxytocin antagonist is administered to the subject in 1 to 10 doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, prior to embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 1 to 10 doses every 24 hours, such as 1 dose every 24 hours, 2 doses every 24 hours, 3 doses every 24 hours, 4 doses every 24 hours, 5 doses every 24 hours, 6 doses every 24 hours, 7 doses every 24 hours, 8 doses every 24 hours, 9 doses every 24 hours, or 10 doses every 24 hours prior to embryo transfer.

[0063] In some embodiments, the oxytocin antagonist is administered to the subject in 1 to 5 doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or more, prior to embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10 to 20 doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or more, prior to embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10-15 doses, for example, every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, prior to embryo transfer.

[0064] In some embodiments, the oxytocin antagonist is administered to the subject in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours or more prior to embryo transfer.

[0065] In some embodiments, the oxytocin antagonist is administered to the subject prior to embryo transfer at up to seven doses every 24 hours (e.g., 1, 2, 3, 4, 5, 6, or 7 doses). In some embodiments, the oxytocin antagonist is administered to the subject prior to embryo transfer at one dose every 24 hours, such as one dose every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject prior to embryo transfer at two doses every 24 hours, such as two doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject prior to embryo transfer at three doses every 24 hours, such as three doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject prior to embryo transfer at four doses every 24 hours, such as four doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject prior to embryo transfer at five doses every 24 hours, such as five doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject prior to embryo transfer at six doses every 24 hours, such as six doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject prior to embryo transfer at seven doses every 24 hours, such as seven doses every 24 hours of Compound (II) below.

[0066] Multiple doses may be administered, for example, beginning about 1 hour to about 14 days, or more, prior to embryo transfer. In some embodiments, multiple doses are administered beginning about 1 hour to about 7 days, or more, prior to embryo transfer. In some embodiments, multiple doses may be administered beginning about 1 day to about 14 days prior to embryo transfer. In some embodiments, multiple doses may be administered beginning about 3 days to about 11 days prior to embryo transfer. In some embodiments, multiple doses may be administered beginning about 1 day to about 7 days prior to embryo transfer. In some embodiments, multiple doses may be administered beginning about 2 days to about 5 days prior to embryo transfer. In some embodiments, multiple doses may be administered beginning about 3 days to about 4 days prior to embryo transfer. For example, multiple doses can be administered beginning 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or more prior to embryo transfer into the subject.

[0067] In some embodiments, multiple doses are administered beginning about two days prior to embryo transfer.

[0068] In some embodiments, multiple doses are administered beginning about 3 days prior to embryo transfer.

[0069] In some embodiments, multiple doses are administered beginning about 4 days prior to embryo transfer.

[0070] In some embodiments, multiple doses are administered beginning about 5 days prior to embryo transfer.

[0071] In some embodiments, multiple doses are administered beginning about 6 days prior to embryo transfer.

[0072] In some embodiments, multiple doses are administered beginning about 7 days prior to embryo transfer.

[0073] In some embodiments, the multiple doses terminate on the day of embryo transfer into the subject, hi some embodiments, the multiple doses terminate with a final dose of the oxytocin antagonist administered simultaneously (e.g., within 60 minutes) with the transfer of one or more embryos into the subject.

[0074] In some embodiments of any of the above aspects of the disclosure, multiple doses continue after embryo transfer. For example, the oxytocin antagonist may be administered to the subject in one or more additional doses simultaneously with embryo transfer. In some embodiments, the oxytocin antagonist is administered within about 1 hour to about 1 week, or longer (e.g., about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, or 142 hours) after transfer of one or more embryos to the subject.

[00130] The subject may receive one or more additional doses (e.g., multiple periodic administrations) after embryo transfer, such as one or more additional doses administered within 144 hours, 156 hours, 168 hours, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, or more).

[0075] For example, in some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 24 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 12 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 12 hours to about 24 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 10 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 9 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 8 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 7 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 6 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 5 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 4 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 2 hours to about 6 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 3 hours to about 5 hours after transfer of one or more embryos to the subject.

[0076] In some embodiments, the oxytocin antagonist is administered to the subject in one or more additional doses beginning about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or more, after transfer of one or more embryos to the subject.

[0077] In some embodiments, the oxytocin antagonist is administered to the subject in multiple booster doses after embryo transfer, e.g., 1 to 20 booster doses every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is further administered to the subject at 1 to 20 doses every 24 hours after embryo transfer, such as 1 dose every 24 hours, 2 doses every 24 hours, 3 doses every 24 hours, 4 doses every 24 hours, 5 doses every 24 hours, 6 doses every 24 hours, 7 doses every 24 hours, 8 doses every 24 hours, 9 doses every 24 hours, 10 doses every 24 hours, 11 doses every 24 hours, 12 doses every 24 hours, 13 doses every 24 hours, 14 doses every 24 hours, 15 doses every 24 hours, 16 doses every 24 hours, 17 doses every 24 hours, 18 doses every 24 hours, 19 doses every 24 hours, or 20 doses every 24 hours. In some embodiments, the oxytocin antagonist is further administered to the subject at more than 20 doses every 24 hours after embryo transfer.

[0078] For example, in some embodiments, the oxytocin antagonist is administered to the subject in 1 to 10 additional doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is further administered to the subject in 1 to 10 doses every 24 hours after embryo transfer, such as 1 dose every 24 hours, 2 doses every 24 hours, 3 doses every 24 hours, 4 doses every 24 hours, 5 doses every 24 hours, 6 doses every 24 hours, 7 doses every 24 hours, 8 doses every 24 hours, 9 doses every 24 hours, or 10 doses every 24 hours.

[0079] In some embodiments, the oxytocin antagonist is administered to the subject in 1 to 5 additional doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10 to 20 additional doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10-15 additional doses, for example, every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, following embryo transfer.

[0080] In some embodiments, the oxytocin antagonist is administered to the subject in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more additional doses, for example, every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours or longer after embryo transfer.

[0081] In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in up to seven additional doses every 24 hours (e.g., 1, 2, 3, 4, 5, 6, or 7 doses). In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in one dose every 24 hours, such as one additional dose every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in two doses every 24 hours, such as two additional doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in three doses every 24 hours, such as three additional doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in four doses every 24 hours, such as four additional doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in five doses every 24 hours, such as five additional doses every 24 hours of Compound (II): In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in six doses every 24 hours, such as six additional doses every 24 hours of Compound (II): In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in seven doses every 24 hours, such as seven additional doses every 24 hours of Compound (II):

[0082] If one or more additional doses of oxytocin antagonist are administered to the subject after embryo transfer, administration of the oxytocin antagonist may be terminated, for example, within about 1 hour to about 14 days, or more, after embryo transfer. For example, administration of the oxytocin antagonist may be terminated within about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or more after embryo transfer.

[0083] Thus, in some embodiments, the oxytocin antagonist is administered to the subject in an additional daily dose after embryo transfer for about 1 day to about 14 days after embryo transfer. In some embodiments, the additional daily dose is administered to the subject for about 3 days to about 11 days after embryo transfer. In some embodiments, the additional daily dose is administered to the subject for 7 days after embryo transfer.

[0084] In another aspect, the present disclosure provides a method for administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered in an amount of about 1,500 mg to about 2,700 mg per dose (e.g., about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,840 mg to about 1,850 mg per dose, about 1,850 mg to about 1,860 mg per dose, about 1,870 mg to about 1,880 mg per dose, about 1,890 mg to about 2,920 mg per dose, about 1,940 mg to about 2,950 mg per dose, about 1,960 mg to about 2,970 mg per dose, about 1,980 mg to about 2,990 mg per dose, about 1,990 mg to about 2,990 mg per dose, about 2,000 mg to about 2,0 ... 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg per dose, about 1,792 mg to about 1,808 mg per dose, about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose, for example about 1,500 mg per dose, 1,666 0mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820 mg, 1,830 mg, 1,840 mg, 1,850 mg, 1,860 mg, 1,870 mg, 1,880 mg, 1,890 mg, 1,900 mg, 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg, e.g., about 1,000 mg per dose.In an amount of 800 mg, or about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,408 mg per dose, The compound is administered to a subject in an amount of about 2,393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose, for example, in an amount of about 2,400 mg per dose (for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), The oxytocin antagonist is administered concurrently with the implantation of one or more embryos (eg, one, two, three, or more embryos) into the subject's uterus.

[0085] In another aspect, the present disclosure provides a method for administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses) totaling about 1,500 mg to about 2,700 mg (e.g., totaling about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg). , about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, a total of 1,500 mg. 00mg, 1,510mg, 1,520mg, 1,530mg, 1,540mg, 1,550mg, 1,560mg, 1,570mg, 1,580mg, 1,590mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,6 50mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,80 0mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or 2,In one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses of about 1,800 mg total (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), or in a total of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg , about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 7 , 10 or more doses), for example, a total of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530 mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690 mg, or 2,700 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), The oxytocin antagonist is administered concurrently with the implantation of one or more embryos (eg, one, two, three, or more embryos) into the subject's uterus.

[0086] In a further aspect, the present disclosure provides a method for administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered in a single dose of about 1,500 mg to about 2,700 mg (e.g., on the day of embryo transfer therapy) (e.g., about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,819 mg to about 1,920 mg, about 1,821 mg to about 1,922 mg, about 1,824 mg to about 1,925 mg, about 1,826 mg to about 1,927 mg, about 1,828 mg to about 1,929 mg, about 1,830 mg to about 1,930 mg, about 1,831 mg to about 1,932 mg, about 1,833 mg to about 1,934 mg, about 1,835 mg to about 1,936 mg, about 1,837 mg to about 1,938 mg, about 1,839 mg to about 1,940 mg, about 1,841 mg to about 1,942 mg, about 1,843 mg to about 1,944 mg, about 1,845 mg to about 1,946 mg, about 1,848 mg to about 1,9 A single dose of 793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg, 1,690 mg, 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg 620mg, 1,630mg, 1,640mg, 1,650mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770m g, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1, In a single dose of 930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg (e.g., on the day of embryo transfer therapy), for example, in a single dose of about 1,800 mg (e.g., on the day of embryo transfer therapy), or about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,700 mg,600mg, about 2,250mg to about 2,550mg, about 2,300mg to about 2,500mg, about 2,350mg to about 2,450mg, about 2,360mg to about 2,440mg, about 2,370mg to about 2,430mg, about 2,380mg to about 2,420mg, about 2,390m g ~ approx. 2,410 mg, approx. 2,391 mg ~ approx. 2,409 mg, approx. 2,392 mg ~ approx. 2,408 mg, approx. 2,393 mg ~ approx. 2,407 mg, approx. A single dose of 397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., on the day of embryo transfer therapy) may be administered, for example, at a dose of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290 mg, 2,300 mg, 2,400 mg, 2,410 mg, 2,420 mg, 2,430 mg, 2,440 mg, 2,450 mg, 2,460 mg, 2,470 mg, 2,480 mg, 2,490 mg, 2,500 mg, 2,510 mg, 2,520 mg, 2,530 mg, 2,540 mg, 2,550 mg, 2,560 mg, 2,570 mg, 2,580 mg, 2,590 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 397 mg, 397 mg, 397 mg, 397 mg, 397 mg, 397 mg, 397 mg, 397 mg, mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg , 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2 The compound is administered to a subject in a single dose of about 2,400 mg (e.g., on the day of embryo transfer therapy), for example, in a single dose of about 2,610 mg, 2,620 mg, 2,630 mg, 2,640 mg, 2,650 mg, 2,660 mg, 2,670 mg, 2,680 mg, 2,690 mg, or 2,700 mg (e.g., on the day of embryo transfer therapy), for example, in a single dose of about 2,400 mg (e.g., on the day of embryo transfer therapy) (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), The oxytocin antagonist is administered concurrently with the implantation of one or more embryos (eg, one, two, three, or more embryos) into the subject's uterus.

[0087] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0088] In some embodiments of any of the above aspects of the present disclosure, the administration reduces the likelihood of embryo implantation failure and / or miscarriage.

[0089] In another aspect, the disclosure provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject administers a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof is administered simultaneously; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to a subject in an amount of about 1,500 mg to about 2,700 mg per dose. For example, the compound may be administered in an amount of about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,790 mg to about 1,810 mg per dose, about 1,791 mg to about 1,809 mg per dose, or about 1,792 mg to about 1,830 mg per dose. The compound may be administered to a subject in an amount of about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0090] In some embodiments, the compound is administered at a dose of about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,450 mg per dose, about 2,450 mg to about 2,460 mg per dose, about 2,460 mg to about 2,470 mg per dose, about 2,470 mg to about 2,480 mg per dose, about 2,480 mg to about 2,490 mg per dose, about 2,491 mg to about 2,492 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,50 ... The compound is administered to a subject in an amount of about 2,408 mg, about 2,393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0091] In some embodiments, the compound is administered in an amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg, 1,690 mg, 1,700 mg, 1,710 mg, 1,720 mg, 1,730 mg, 1,740 mg, 1,750 mg, 1,760 mg, 1,770 mg, 1,780 mg, 1,790 mg, 2,800 mg, 2,810 mg, 2,820 mg, 2,830 mg, 2,840 mg, 2,850 mg, 2,860 mg, 2,870 mg, 2,880 mg, 2,890 mg, 3,900 mg, 3,910 mg, 3,920 mg, 3,930 mg, 3,940 mg, 3,950 mg, 3,960 mg, 3,970 mg, 3,980 mg, 3,990 mg, 4,000 mg, 4,010 mg, 4,020 mg, 4,030 mg, 4,040 mg, 4,050 mg, 4,060 mg, 4,070 mg, 4,080 mg, 4,090 mg, 5,100 mg, 5,110 mg, 5 670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1, 770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,8 70mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,9 70mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,07 The compound is administered to a subject in an amount of 0 mg, 2,080 mg, 2,090 mg, or 2,100 mg, for example, in an amount of about 1,800 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0092] In some embodiments, the compound is administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 300 mg, 301 mg, 302 mg, 303 mg, 304 mg, 305 mg, 306 mg, 307 mg, 308 mg, 309 mg, 310 mg, 311 mg, 312 mg, 313 mg, 314 mg, 315 mg, 316 mg, 317 mg, 318 mg, 319 mg, 320 mg, 321 mg, 322 mg, 323 mg, 324 mg, 325 mg, 326 mg, 327 mg, 328 mg, 329 mg, 330 mg, 331 mg, 332 mg, 333 mg, 334 mg, 335 mg, 336 mg, 337 mg, 338 mg, 339 mg, 340 mg, 341 mg, 342 mg, 343 mg, 3 270mg, 2,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2, 370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,4 70mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,5 70mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,67 The compound is administered to a subject in an amount of 0 mg, 2,680 mg, 2,690 mg, or 2,700 mg, for example, in an amount of about 2,400 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0093] In some embodiments, the compound is administered in an amount of about 1,600 mg to about 2,600 mg per dose, e.g., about 1,610 mg to about 2,590 mg per dose, about 1,620 mg to about 2,580 mg per dose, about 1,630 mg to about 2,570 mg per dose, about 1,640 mg to about 2,560 mg per dose, about 1,650 mg to about 2,550 mg per dose, about 1,660 mg to about 2,540 mg per dose, about 1,670 mg to about 2,530 mg per dose, about 1,680 mg to about 2,520 mg per dose, about 1,690 mg to about 2,5 ... 10 mg, about 1,700 mg to about 2,500 mg per dose, about 1,710 mg to about 2,490 mg per dose, about 1,720 mg to about 2,480 mg per dose, about 1,730 mg to about 2,470 mg per dose, about 1,740 mg to about 2,460 mg per dose, about 1,750 mg to about 2,450 mg per dose, about 1,760 mg to about 2,440 mg per dose, about 1,770 mg to about 2,430 mg per dose, about 1,780 mg to about 2,420 mg per dose, about 1,790 mg to about 2,410 mg per dose, about 1,800 mg to about 2,500 mg per dose 2,400 mg, about 1,810 mg to about 2,390 mg per dose, about 1,820 mg to about 2,380 mg per dose, about 1,830 mg to about 2,370 mg per dose, about 1,840 mg to about 2,360 mg per dose, about 1,850 mg to about 2,350 mg per dose, about 1,860 mg to about 2,340 mg per dose, about 1,870 mg to about 2,330 mg per dose, about 1,880 mg to about 2,320 mg per dose, about 1,890 mg to about 2,310 mg per dose, about 1,900 mg to about 2,300 mg per dose, about 1,910 mg to about 2,360 mg per dose mg to about 2,290 mg per dose, about 1,920 mg to about 2,280 mg per dose, about 1,930 mg to about 2,270 mg per dose, about 1,940 mg to about 2,260 mg per dose, about 1,950 mg to about 2,250 mg per dose, about 1,960 mg to about 2,240 mg per dose, about 1,970 mg to about 2,230 mg per dose, about 1,980 mg to about 2,220 mg per dose, about 1,990 mg to about 2,210 mg per dose, about 2,000 mg to about 2,200 mg per dose, about 2,010 mg to about 2,190 mg per dose, about 2,The compound is administered to a subject in an amount of about 0.020 mg to about 2,180 mg per dose, about 2,030 mg to about 2,170 mg per dose, about 2,040 mg to about 2,160 mg per dose, about 2,050 mg to about 2,150 mg per dose, about 2,060 mg to about 2,140 mg per dose, about 2,070 mg to about 2,130 mg per dose, about 2,080 mg to about 2,120 mg per dose, or about 2,090 mg to about 2,110 mg per dose, for example, about 2,100 mg per dose, for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0094] In another aspect, the disclosure provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject administers a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof is administered simultaneously; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to the subject in one or more doses (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling from about 1,500 mg to about 2,700 mg. For example, the compound may be administered in a total amount of about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,810 mg, about 1,815 mg to about 1,820 mg, about 1,825 mg to about 1,830 mg, about 1,835 mg to about 1,840 mg, about 1,845 mg to about 1,850 mg, about 1,850 mg to about 1,860 mg, about 1,865 mg to about 1,870 mg, about 1,875 mg to about 1,880 mg, about 1,885 mg to about 1,890 mg, about 1,891 mg to about 1,892 mg, about 1,893 mg to about 1,894 mg, about 1,895 mg to about 2,000 mg, about 1,896 mg to about 2,000 mg, about 1,897 mg to about 2,000 mg, about 1,898 mg to about 2 The compound may be administered to a subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0095] In some embodiments, the compound is administered in a total amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 2,406 mg, about 2,395 mg, about 2,405 mg, about 2,396 mg, about 2,404 mg, about 2,397 mg, about 2,403 mg, about 2,398 mg, about 2,402 mg, or about 2,399 mg, about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0096] In some embodiments, the compound is administered in a total amount of 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg , 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,79 0mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1, 900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or 2,100mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, in an amount of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0097] In some embodiments, the compound is administered in a total amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg g, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,3 90mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690mg, or 2,700mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0098] In some embodiments, the compound is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,600 mg to about 2,600 mg, for example, a total of about 1,610 mg to about 2,590 mg, about 1,620 mg to about 2,580 mg, about 1,630 mg to about 2,570 mg, about 1,640 mg to about 2,560 mg, about 1,650 mg to about 2,550 mg, about 1,660 mg to about 2,540 mg, about 1,670 mg to about 2,530 mg, about 1,680 mg to about 2,520 mg, about 1,690 mg to about 2,510mg, about 1,700mg to about 2,500mg, about 1,710mg to about 2,490mg, about 1,720mg to about 2,480mg, about 1,730mg to about 2,470mg, about 1,740mg to about 2,460mg, about 1,750mg to about 2,450mg, about 1,760m g~2,440mg, 1,770mg~2,430mg, 1,780mg~2,420mg, 1,790mg~2,410mg, 1,800mg~2,400mg, 1,810mg~2,390mg, 1,820mg~2,380mg, 1,8 30mg to about 2,370mg, about 1,840mg to about 2,360mg, about 1,850mg to about 2,350mg, about 1,860mg to about 2,340mg, about 1,870mg to about 2,330mg, about 1,880mg to about 2,320mg, about 1,890mg to about 2,310mg, Approximately 1,900mg to approximately 2,300mg, approximately 1,910mg to approximately 2,290mg, approximately 1,920mg to approximately 2,280mg, approximately 1,930mg to approximately 2,270mg, approximately 1,940mg to approximately 2,260mg, approximately 1,950mg to approximately 2,250mg, approximately 1,960mg to approximately 2,240 mg, about 1,970 mg to about 2,230 mg, about 1,980 mg to about 2,220 mg, about 1,990 mg to about 2,210 mg, about 2,000 mg to about 2,200 mg, about 2,010 mg to about 2,190 mg, about 2,020 mg to about 2,180 mg, about 2,030 mg to about 2,170 mg, about 2,040 mg to about 2,160 mg, about 2,050 mg to about 2,150 mg, about 2,060 mg to about 2,140 mg, about 2,070 mg to about 2,130 mg, about 2,080 mg to about 2,120 mg, or about 2,090 mg to about 2,110 mg, for example, about 2,The compound is administered to the subject in one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0099] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0100] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0101] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0102] In a further aspect, the present disclosure provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject administers a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof is administered simultaneously; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to the subject (eg, on the day of embryo transfer therapy) in a single dose of about 1,500 mg to about 2,700 mg. For example, the compound may be administered in an amount of about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, or about 1,793 mg to about 1,807 mg. The compound may be administered to a subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0103] In some embodiments, the compound is administered in an amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,419 mg, The compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0104] In some embodiments, the compound is administered in an amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1 ,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1, 780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,88 0mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980 mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg , 2,090 mg, or 2,100 mg in a single dose (e.g., on the day of embryo transfer therapy), for example, in an amount of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0105] In some embodiments, the compound is administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 2,400 mg, 2,410 mg, 2,420 mg, 2,430 mg, 2,440 mg, 2,450 mg, 2,460 mg, 2,470 mg, 2,480 mg, 2,490 mg, 300 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 3450 mg, 3460 mg, 3470 mg, 350 mg, 350 mg, 350 mg, 360 mg, 375 mg, 380 mg, 385 mg, 386 mg, 387 mg, 388 mg, 389 mg, 390 mg, 391 mg, 392 mg, 393 mg, 394 mg, 395 mg, 396 mg, 397 mg, 398 mg, 399 mg, 400 mg, 401 mg ,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2, 380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,48 0mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580 mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg , 2,690 mg, or 2,700 mg in a single dose (e.g., on the day of embryo transfer therapy), for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0106] In some embodiments, the compound is administered in a single dose of about 1,600 mg to about 2,600 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,610 mg to about 2,590 mg, about 1,620 mg to about 2,580 mg, about 1,630 mg to about 2,570 mg, about 1,640 mg to about 2,560 mg, about 1,650 mg to about 2,550 mg, about 1,660 mg to about 2,540 mg, about 1,670 mg to about 2,530 mg, about 1,680 mg to about 2,520 mg, about 1,690 mg to about 2,510 mg, or about 1,700 mg to about 2,500 mg , about 1,710mg to about 2,490mg, about 1,720mg to about 2,480mg, about 1,730mg to about 2,470mg, about 1,740mg to about 2,460mg, about 1,750mg to about 2,450mg, about 1,760mg to about 2,440mg, about 1,770mg Approximately 2,430mg, approximately 1,780mg to approximately 2,420mg, approximately 1,790mg to approximately 2,410mg, approximately 1,800mg to approximately 2,400mg, approximately 1,810mg to approximately 2,390mg, approximately 1,820mg to approximately 2,380mg, approximately 1,830mg to approximately 2,370mg, approximately 1 ,840mg~about 2,360mg,about 1,850mg~about 2,350mg,about 1,860mg~about 2,340mg,about 1,870mg~about 2,330mg,about 1,880mg~about 2,320mg,about 1,890mg~about 2,310mg,about 1,900mg~about 2, 300mg, about 1,910mg to about 2,290mg, about 1,920mg to about 2,280mg, about 1,930mg to about 2,270mg, about 1,940mg to about 2,260mg, about 1,950mg to about 2,250mg, about 1,960mg to about 2,240mg, about 1,97 0 mg to about 2,230 mg, about 1,980 mg to about 2,220 mg, about 1,990 mg to about 2,210 mg, about 2,000 mg to about 2,200 mg, about 2,010 mg to about 2,190 mg, about 2,020 mg to about 2,180 mg, about 2,030 mg to about 2,170 mg, about 2,040 mg to about 2,160 mg, about 2,050 mg to about 2,150 mg, about 2,060 mg to about 2,140 mg, about 2,070 mg to about 2,130 mg, about 2,080 mg to about 2,120 mg, or about 2,090 mg to about 2,110 mg, for example, about 2,A single dose of 100 mg is administered to the subject (e.g., on the day of embryo transfer therapy), and the compound is, for example, (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0107] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0108] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0109] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0110] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0111] In some embodiments of any of the above aspects of the present disclosure, administration of the oxytocin antagonist reduces the likelihood of embryo implantation failure and / or miscarriage.

[0112] In another aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered in an amount of about 1,500 mg to about 2,700 mg per dose (e.g., about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,840 mg to about 1,850 mg per dose, about 1,850 mg to about 1,860 mg per dose, about 1,870 mg to about 1,880 mg per dose, about 1,890 mg to about 2,920 mg per dose, about 1,940 mg to about 2,950 mg per dose, about 1,960 mg to about 2,970 mg per dose, about 1,980 mg to about 2,990 mg per dose, about 1,990 mg to about 2,990 mg per dose, about 2,000 mg to about 2,0 ... 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg per dose, about 1,792 mg to about 1,808 mg per dose, about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose, for example about 1,500 mg per dose, 1,666 0mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820 mg, 1,830 mg, 1,840 mg, 1,850 mg, 1,860 mg, 1,870 mg, 1,880 mg, 1,890 mg, 1,900 mg, 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg, e.g., about 1,000 mg per dose.In an amount of 800 mg, or about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,408 mg per dose, about 2,410 mg to about 2,420 ... 393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose, for example, about 2,400 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), and b. A method of treating a subject undergoing embryo transfer therapy by administering an oxytocin antagonist concomitantly with the transfer of one or more embryos (e.g., one, two, three, or more embryos) to the uterus of the subject is provided.

[0113] In another aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses) totaling about 1,500 mg to about 2,700 mg (e.g., totaling about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg). , about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, a total of 1,500 mg. 00mg, 1,510mg, 1,520mg, 1,530mg, 1,540mg, 1,550mg, 1,560mg, 1,570mg, 1,580mg, 1,590mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,6 50mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,80 0mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or 2,In one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses of about 1,800 mg total (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), or in a total of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg , about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 7 , 10 or more doses), for example, a total of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530 mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690 mg, or 2,700 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime) represented by Formula (II)); b. A method of treating a subject undergoing embryo transfer therapy by administering an oxytocin antagonist concomitantly with the transfer of one or more embryos (e.g., one, two, three, or more embryos) to the uterus of the subject is provided.

[0114] In a further aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered (e.g., on the day of embryo transfer therapy) in a single dose of about 1,500 mg to about 2,700 mg (e.g., about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,810 mg to about 1,820 mg, about 1,830 mg to about 1,840 mg, about 1,850 mg to about 1,850 mg, about 1,860 mg to about 1,870 mg, about 1,880 mg to about 1,890 mg, about 1,891 mg to about 2,920 mg, about 1,892 mg to about 2,930 mg, about 1,893 mg to about 2,940 mg, about 1,894 mg to about 2,950 mg, about 1,895 mg to about 2,960 mg, about 1,895 mg to about 2,970 mg, about 1,895 mg to about 2,980 mg, about 1,895 mg to about 2,995 mg, about 2,995 mg to about 3,000 mg, about 2,000 mg to about 3,0 A single dose of 792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,650mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,75 0mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, In a single dose of 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg (e.g., on the day of embryo transfer therapy), for example, in a single dose of about 1,800 mg (e.g., on the day of embryo transfer therapy), or about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,700 mg650mg, about 2,200mg to about 2,600mg, about 2,250mg to about 2,550mg, about 2,300mg to about 2,500mg, about 2,350mg to about 2,450mg, about 2,360mg to about 2,440mg, about 2,370mg to about 2,430mg, about 2,380mg Approximately 2,420mg, approximately 2,390mg to approximately 2,410mg, approximately 2,391mg to approximately 2,409mg, approximately 2,392mg to approximately 2,408mg, approximately 2,393mg to approximately 2,407mg, approximately 2,394mg to approximately 2,406mg, approximately 2,395mg to approximately 2,405mg, approximately 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., on the day of embryo transfer therapy), e.g., about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,4 40mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590m g, 2,600 mg, 2,610 mg, 2,620 mg, 2,630 mg, 2,640 mg, 2,650 mg, 2,660 mg, 2,670 mg, 2,680 mg, 2,690 mg, or 2,700 mg (e.g., on the day of embryo transfer therapy), for example, in an amount of about 2,400 mg to a subject (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)); b. A method of treating a subject undergoing embryo transfer therapy by administering an oxytocin antagonist concomitantly with the transfer of one or more embryos (e.g., one, two, three, or more embryos) to the uterus of the subject is provided.

[0115] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0116] In some embodiments of any of the above aspects of the present disclosure, the administration reduces the likelihood of embryo implantation failure and / or miscarriage.

[0117] In some embodiments, the oxytocin antagonist is administered to the subject simultaneously with embryo transfer in a single dose.

[0118] In some embodiments, the oxytocin antagonist is administered to the subject in multiple doses beginning during embryo transfer (e.g., in multiple periodic doses) and continuing after embryo transfer, such as 1 to 20 doses beginning during embryo transfer and continuing after embryo transfer, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer. For example, in some embodiments, the oxytocin antagonist is administered to the subject in 1 to 10 doses beginning during and continuing after embryo transfer, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 1 to 5 doses beginning during and continuing after embryo transfer, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10-20 doses beginning during and continuing after embryo transfer, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10-15 doses beginning during and continuing after embryo transfer, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer.In some embodiments, the oxytocin antagonist is administered to the subject in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or more, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in up to 7 doses (e.g., 1, 2, 3, 4, 5, 6, or 7 doses) every 24 hours, starting during embryo transfer and continuing after embryo transfer.

[0119] For example, in some embodiments, an oxytocin antagonist is first administered to a subject simultaneously with the transfer of one or more embryos into the subject's uterus, and the oxytocin antagonist is then administered to the subject in one or more booster doses within about 1 hour to about 24 hours after the transfer of one or more embryos into the subject. For example, in some embodiments, an oxytocin antagonist is administered to a subject in one or more booster doses within about 1 hour to about 12 hours after the transfer of one or more embryos into the subject. In some embodiments, an oxytocin antagonist is administered to a subject in one or more booster doses within about 12 hours to about 24 hours after the transfer of one or more embryos into the subject. In some embodiments, an oxytocin antagonist is administered to a subject in one or more booster doses within about 1 hour to about 10 hours after the transfer of one or more embryos into the subject. In some embodiments, an oxytocin antagonist is administered to a subject in one or more booster doses within about 1 hour to about 9 hours after the transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 8 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 7 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 6 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 5 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 1 hour to about 4 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 2 hours to about 6 hours after transfer of one or more embryos to the subject. In some embodiments, the oxytocin antagonist is administered to the subject in one or more booster doses within about 3 hours to about 5 hours after transfer of one or more embryos to the subject.

[0120] In some embodiments, the oxytocin antagonist is first administered to the subject simultaneously with the transfer of one or more embryos into the subject's uterus, and the oxytocin antagonist is subsequently administered to the subject in one or more additional doses beginning about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or more after the transfer of the one or more embryos into the subject.

[0121] In some embodiments, the oxytocin antagonist is first administered to the subject simultaneously with the transfer of one or more embryos into the subject's uterus, and the oxytocin antagonist is then administered to the subject in multiple booster doses after embryo transfer, such as 1 to 20 booster doses every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is further administered to the subject at 1 to 20 doses every 24 hours after embryo transfer, such as 1 dose every 24 hours, 2 doses every 24 hours, 3 doses every 24 hours, 4 doses every 24 hours, 5 doses every 24 hours, 6 doses every 24 hours, 7 doses every 24 hours, 8 doses every 24 hours, 9 doses every 24 hours, 10 doses every 24 hours, 11 doses every 24 hours, 12 doses every 24 hours, 13 doses every 24 hours, 14 doses every 24 hours, 15 doses every 24 hours, 16 doses every 24 hours, 17 doses every 24 hours, 18 doses every 24 hours, 19 doses every 24 hours, or 20 doses every 24 hours. In some embodiments, the oxytocin antagonist is further administered to the subject at more than 20 doses every 24 hours after embryo transfer.

[0122] For example, in some embodiments, an oxytocin antagonist is first administered to a subject simultaneously with the implantation of one or more embryos into the subject's uterus, and the compound is then administered to the subject in 1 to 10 additional doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo implantation. In some embodiments, the oxytocin antagonist is further administered to the subject after embryo transfer at 1 to 10 doses every 24 hours, such as 1 dose every 24 hours, 2 doses every 24 hours, 3 doses every 24 hours, 4 doses every 24 hours, 5 doses every 24 hours, 6 doses every 24 hours, 7 doses every 24 hours, 8 doses every 24 hours, 9 doses every 24 hours, or 10 doses every 24 hours.

[0123] For example, in some embodiments, an oxytocin antagonist is first administered to a subject simultaneously with the transfer of one or more embryos into the subject's uterus, and the oxytocin antagonist is then administered to the subject in 1 to 5 additional doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10-20 additional doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10-15 additional doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer.

[0124] In some embodiments, the oxytocin antagonist is first administered to the subject simultaneously with the implantation of one or more embryos into the subject's uterus, and the compound is subsequently administered to the subject in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more additional doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo implantation.

[0125] In some embodiments, the oxytocin antagonist is first administered to the subject simultaneously with the implantation of one or more embryos into the subject's uterus, and the oxytocin antagonist is then administered to the subject after embryo transfer in up to seven additional doses (e.g., 1, 2, 3, 4, 5, 6, or 7 doses) every 24 hours. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in one dose every 24 hours, such as one additional dose every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in two doses every 24 hours, such as two additional doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in three doses every 24 hours, such as three additional doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in four doses every 24 hours, such as four additional doses every 24 hours of Compound (II): In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in five doses every 24 hours, such as five additional doses every 24 hours of Compound (II): In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in six doses every 24 hours, such as six additional doses every 24 hours of Compound (II): In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in seven doses every 24 hours, such as seven additional doses every 24 hours of Compound (II):

[0126] If one or more additional doses of oxytocin antagonist are administered to the subject after embryo transfer, administration of the oxytocin antagonist may be terminated, for example, within about 1 hour to about 14 days, or more, after embryo transfer. For example, administration of the oxytocin antagonist may be terminated within about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or more after embryo transfer.

[0127] Thus, in some embodiments, an oxytocin antagonist is first administered to a subject contemporaneously with the transfer of one or more embryos into the subject's uterus, and the oxytocin antagonist is then administered to the subject in additional daily doses after embryo transfer for about 1 day to about 14 days after embryo transfer. In some embodiments, the additional daily doses are administered to the subject for about 3 days to about 11 days after embryo transfer. In some embodiments, the additional daily doses are administered to the subject for 7 days after embryo transfer.

[0128] In another aspect, the present disclosure provides a method for administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered in an amount of about 1,500 mg to about 2,700 mg per dose (e.g., about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,840 mg to about 1,850 mg per dose, about 1,850 mg to about 1,860 mg per dose, about 1,870 mg to about 1,880 mg per dose, about 1,890 mg to about 2,920 mg per dose, about 1,940 mg to about 2,950 mg per dose, about 1,960 mg to about 2,970 mg per dose, about 1,980 mg to about 2,990 mg per dose, about 1,990 mg to about 2,990 mg per dose, about 2,000 mg to about 2,0 ... 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg per dose, about 1,792 mg to about 1,808 mg per dose, about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose, for example about 1,500 mg per dose, 1,666 0mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820 mg, 1,830 mg, 1,840 mg, 1,850 mg, 1,860 mg, 1,870 mg, 1,880 mg, 1,890 mg, 1,900 mg, 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg, e.g., about 1,000 mg per dose.In an amount of 800 mg, or about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,408 mg per dose, The compound is administered to a subject in an amount of about 2,393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose, for example, in an amount of about 2,400 mg per dose (for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), The oxytocin antagonist is administered to the subject after transfer of one or more embryos (eg, one, two, three, or more embryos) into the subject's uterus.

[0129] In another aspect, the present disclosure provides a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses) totaling about 1,500 mg to about 2,700 mg (e.g., totaling about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg). , about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, a total of 1,500 mg. 00mg, 1,510mg, 1,520mg, 1,530mg, 1,540mg, 1,550mg, 1,560mg, 1,570mg, 1,580mg, 1,590mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,6 50mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,80 0mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or 2,In one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses of about 1,800 mg total (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), or in a total of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg , about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 7 , 10 or more doses), for example, a total of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530 mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690 mg, or 2,700 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), The oxytocin antagonist is administered to the subject after transfer of one or more embryos (eg, one, two, three, or more embryos) into the subject's uterus.

[0130] In a further aspect, the present disclosure provides a method for administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, to treat a subject undergoing embryo transfer therapy; In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered (e.g., on the day of embryo transfer therapy) in a single dose of about 1,500 mg to about 2,700 mg (e.g., about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,810 mg to about 1,820 mg, about 1,830 mg to about 1,840 mg, about 1,850 mg to about 1,850 mg, about 1,860 mg to about 1,870 mg, about 1,880 mg to about 1,890 mg, about 1,891 mg to about 2,920 mg, about 1,892 mg to about 2,930 mg, about 1,893 mg to about 2,940 mg, about 1,894 mg to about 2,950 mg, about 1,895 mg to about 2,960 mg, about 1,895 mg to about 2,970 mg, about 1,895 mg to about 2,980 mg, about 1,895 mg to about 2,995 mg, about 2,995 mg to about 3,000 mg, about 2,000 mg to about 3,0 A single dose of 792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,650mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,75 0mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, In a single dose of 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg (e.g., on the day of embryo transfer therapy), for example, in a single dose of about 1,800 mg (e.g., on the day of embryo transfer therapy), or about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,700 mg650mg, about 2,200mg to about 2,600mg, about 2,250mg to about 2,550mg, about 2,300mg to about 2,500mg, about 2,350mg to about 2,450mg, about 2,360mg to about 2,440mg, about 2,370mg to about 2,430mg, about 2,380mg ~2,420mg, 2,390mg~2,410mg, 2,391mg~2,409mg, 2,392mg~2,408mg, 2,393mg~2,407mg, 2,394mg~2,406mg, 2,395mg~2,405mg, 2,3 A single dose of 96 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., on the day of embryo transfer therapy), e.g., about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 2,410 mg, 2,420 mg, 2,430 mg, 2,440 mg, 2,450 mg, 2,460 mg, 2,470 mg, 2,480 mg, 2,490 mg, 30 ... 0mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430m g, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, and administering to the subject (e.g., on the day of embryo transfer therapy) a single dose of 2,590 mg, 2,600 mg, 2,610 mg, 2,620 mg, 2,630 mg, 2,640 mg, 2,650 mg, 2,660 mg, 2,670 mg, 2,680 mg, 2,690 mg, or 2,700 mg, for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), The oxytocin antagonist is administered to the subject after transfer of one or more embryos (eg, one, two, three, or more embryos) into the subject's uterus.

[0131] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0132] In some embodiments, administration reduces the likelihood of embryo implantation failure and / or miscarriage.

[0133] In another aspect, the present disclosure provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject then administers a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to a subject in an amount of about 1,500 mg to about 2,700 mg per dose. For example, the compound may be administered in an amount of about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,790 mg to about 1,810 mg per dose, about 1,791 mg to about 1,809 mg per dose, or about 1,792 mg to about 1,830 mg per dose. The compound may be administered to a subject in an amount of about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0134] In some embodiments, the compound is administered at a dose of about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,450 mg per dose, about 2,450 mg to about 2,460 mg per dose, about 2,460 mg to about 2,470 mg per dose, about 2,470 mg to about 2,480 mg per dose, about 2,480 mg to about 2,490 mg per dose, about 2,491 mg to about 2,492 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,50 ... The compound is administered to a subject in an amount of about 2,408 mg, about 2,393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0135] In some embodiments, the compound is administered in an amount of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg, 1,690 mg, 1,700 mg, 1,710 mg, 1,720 mg, 1,730 mg, 1,740 mg, 1,750 mg, 1,760 mg, 1,770 mg, 1,780 mg, 1,790 mg, 2,800 mg, 2,810 mg, 2,820 mg, 2,830 mg, 2,840 mg, 2,850 mg, 2,860 mg, 2,870 mg, 2,880 mg, 2,890 mg, 3,900 mg, 3,910 mg, 3,920 mg, 3,930 mg, 3,940 mg, 3,950 mg, 3,960 mg, 3,970 mg, 3,980 mg, 3,990 mg, 4,000 mg, 4,010 mg, 4,020 mg, 4,030 mg, 4,040 mg, 4,050 mg, 4,060 mg, 4,070 mg, 4,080 mg, 4,090 mg, 5,100 mg, 5,110 mg, 5 670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1, 770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,8 70mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,9 70mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,07 The compound is administered to a subject in an amount of 0 mg, 2,080 mg, 2,090 mg, or 2,100 mg, for example, in an amount of about 1,800 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0136] In some embodiments, the compound is administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 300 mg, 301 mg, 302 mg, 303 mg, 304 mg, 305 mg, 306 mg, 307 mg, 308 mg, 309 mg, 310 mg, 311 mg, 312 mg, 313 mg, 314 mg, 315 mg, 316 mg, 317 mg, 318 mg, 319 mg, 320 mg, 321 mg, 322 mg, 323 mg, 324 mg, 325 mg, 326 mg, 327 mg, 328 mg, 329 mg, 330 mg, 331 mg, 332 mg, 333 mg, 334 mg, 335 mg, 336 mg, 337 mg, 338 mg, 339 mg, 340 mg, 341 mg, 342 mg, 343 mg, 3 270mg, 2,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2, 370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,4 70mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,5 70mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,67 The compound is administered to a subject in an amount of 0 mg, 2,680 mg, 2,690 mg, or 2,700 mg, for example, in an amount of about 2,400 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0137] In some embodiments, the compound is administered in an amount of about 1,600 mg to about 2,600 mg per dose, e.g., about 1,610 mg to about 2,590 mg per dose, about 1,620 mg to about 2,580 mg per dose, about 1,630 mg to about 2,570 mg per dose, about 1,640 mg to about 2,560 mg per dose, about 1,650 mg to about 2,550 mg per dose, about 1,660 mg to about 2,540 mg per dose, about 1,670 mg to about 2,530 mg per dose, about 1,680 mg to about 2,520 mg per dose, about 1,690 mg to about 2,5 ... 10 mg, about 1,700 mg to about 2,500 mg per dose, about 1,710 mg to about 2,490 mg per dose, about 1,720 mg to about 2,480 mg per dose, about 1,730 mg to about 2,470 mg per dose, about 1,740 mg to about 2,460 mg per dose, about 1,750 mg to about 2,450 mg per dose, about 1,760 mg to about 2,440 mg per dose, about 1,770 mg to about 2,430 mg per dose, about 1,780 mg to about 2,420 mg per dose, about 1,790 mg to about 2,410 mg per dose, about 1,800 mg to about 2,500 mg per dose 2,400 mg, about 1,810 mg to about 2,390 mg per dose, about 1,820 mg to about 2,380 mg per dose, about 1,830 mg to about 2,370 mg per dose, about 1,840 mg to about 2,360 mg per dose, about 1,850 mg to about 2,350 mg per dose, about 1,860 mg to about 2,340 mg per dose, about 1,870 mg to about 2,330 mg per dose, about 1,880 mg to about 2,320 mg per dose, about 1,890 mg to about 2,310 mg per dose, about 1,900 mg to about 2,300 mg per dose, about 1,910 mg to about 2,360 mg per dose mg to about 2,290 mg per dose, about 1,920 mg to about 2,280 mg per dose, about 1,930 mg to about 2,270 mg per dose, about 1,940 mg to about 2,260 mg per dose, about 1,950 mg to about 2,250 mg per dose, about 1,960 mg to about 2,240 mg per dose, about 1,970 mg to about 2,230 mg per dose, about 1,980 mg to about 2,220 mg per dose, about 1,990 mg to about 2,210 mg per dose, about 2,000 mg to about 2,200 mg per dose, about 2,010 mg to about 2,190 mg per dose, about 2,The compound is administered to a subject in an amount of about 0.020 mg to about 2,180 mg per dose, about 2,030 mg to about 2,170 mg per dose, about 2,040 mg to about 2,160 mg per dose, about 2,050 mg to about 2,150 mg per dose, about 2,060 mg to about 2,140 mg per dose, about 2,070 mg to about 2,130 mg per dose, about 2,080 mg to about 2,120 mg per dose, or about 2,090 mg to about 2,110 mg per dose, for example, about 2,100 mg per dose, for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II).

[0138] In another aspect, the present invention provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject then administers a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to the subject in one or more doses (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling from about 1,500 mg to about 2,700 mg. For example, the compound may be administered in a total amount of about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,810 mg, about 1,815 mg to about 1,820 mg, about 1,825 mg to about 1,830 mg, about 1,835 mg to about 1,840 mg, about 1,845 mg to about 1,850 mg, about 1,850 mg to about 1,860 mg, about 1,865 mg to about 1,870 mg, about 1,875 mg to about 1,880 mg, about 1,885 mg to about 1,890 mg, about 1,891 mg to about 1,892 mg, about 1,893 mg to about 1,894 mg, about 1,895 mg to about 2,000 mg, about 1,896 mg to about 2,000 mg, about 1,897 mg to about 2,000 mg, about 1,898 mg to about 2 The compound may be administered to a subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0139] In some embodiments, the compound is administered in a total amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 2,406 mg, about 2,395 mg, about 2,405 mg, about 2,396 mg, about 2,404 mg, about 2,397 mg, about 2,403 mg, about 2,398 mg, about 2,402 mg, or about 2,399 mg, about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0140] In some embodiments, the compound is administered in a total amount of 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg, 1,690 mg, 20 ... 80mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780m g, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1, 890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or or 2,100 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) to the subject (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0141] In some embodiments, the compound is administered in a total amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg g, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,3 90mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690mg, or 2,700mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0142] In some embodiments, the compound is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,600 mg to about 2,600 mg, for example, a total of about 1,610 mg to about 2,590 mg, about 1,620 mg to about 2,580 mg, about 1,630 mg to about 2,570 mg, about 1,640 mg to about 2,560 mg, about 1,650 mg to about 2,550 mg, about 1,660 mg to about 2,540 mg, about 1,670 mg to about 2,530 mg, about 1,680 mg to about 2,520 mg, about 1,690 mg to about 2,510mg, about 1,700mg to about 2,500mg, about 1,710mg to about 2,490mg, about 1,720mg to about 2,480mg, about 1,730mg to about 2,470mg, about 1,740mg to about 2,460mg, about 1,750mg to about 2,450mg, about 1,760m g~2,440mg, 1,770mg~2,430mg, 1,780mg~2,420mg, 1,790mg~2,410mg, 1,800mg~2,400mg, 1,810mg~2,390mg, 1,820mg~2,380mg, 1,8 30mg to about 2,370mg, about 1,840mg to about 2,360mg, about 1,850mg to about 2,350mg, about 1,860mg to about 2,340mg, about 1,870mg to about 2,330mg, about 1,880mg to about 2,320mg, about 1,890mg to about 2,310mg, Approximately 1,900mg to approximately 2,300mg, approximately 1,910mg to approximately 2,290mg, approximately 1,920mg to approximately 2,280mg, approximately 1,930mg to approximately 2,270mg, approximately 1,940mg to approximately 2,260mg, approximately 1,950mg to approximately 2,250mg, approximately 1,960mg to approximately 2,240 mg, about 1,970 mg to about 2,230 mg, about 1,980 mg to about 2,220 mg, about 1,990 mg to about 2,210 mg, about 2,000 mg to about 2,200 mg, about 2,010 mg to about 2,190 mg, about 2,020 mg to about 2,180 mg, about 2,030 mg to about 2,170 mg, about 2,040 mg to about 2,160 mg, about 2,050 mg to about 2,150 mg, about 2,060 mg to about 2,140 mg, about 2,070 mg to about 2,130 mg, about 2,080 mg to about 2,120 mg, or about 2,090 mg to about 2,110 mg, for example, about 2,The compound is administered to the subject in one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), for example, the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0143] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0144] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0145] In some embodiments, the compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses, e.g., a single dose) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II):

[0146] In a further aspect, the present disclosure provides a method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject, wherein the subject then receives a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I): [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered to the subject (eg, on the day of embryo transfer therapy) in a single dose of about 1,500 mg to about 2,700 mg. For example, the compound may be administered in an amount of about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, or about 1,793 mg to about 1,807 mg. The compound may be administered to a subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0147] In some embodiments, the compound is administered in an amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,419 mg, The compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0148] In some embodiments, the compound is administered at a concentration of about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600 mg, 1,610 mg, 1,620 mg, 1,630 mg, 1,640 mg, 1,650 mg, 1,660 mg, 1,670 mg, 1,680 mg, 1,690 mg, 2,700 mg, 2,710 mg, 2,720 mg, 2,730 mg, 2,740 mg, 2,750 mg, 2,760 mg, 2,770 mg, 2,780 mg, 2,790 mg, 3,800 mg, 3,810 mg, 3,820 mg, 3,830 mg, 3,840 mg, 3,850 mg, 3,860 mg, 3,870 mg, 3,880 mg, 3,890 mg, 4,900 mg, 4,910 mg, 4,920 mg, 4,930 mg, 4,940 mg, 4,950 mg, 4,960 mg, 4,970 mg, 4,980 mg, 4,990 mg, 5,000 mg, 5,000 mg, 5,010 mg, 5,020 mg, 5,030 mg, 5,040 mg, 5,050 mg, 5,060 mg, 5,070 mg, 5,080 mg, 5,090 mg, 600 mg, 610 mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,77 0mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,87 0mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,9 70mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,0 The compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of 70 mg, 2,080 mg, 2,090 mg, or 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0149] In some embodiments, the compound is administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 2,400 mg, 2,410 mg, 2,420 mg, 2,430 mg, 2,440 mg, 2,450 mg, 2,460 mg, 2,470 mg, 2,480 mg, 2,490 mg, 300 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 3450 mg, 3460 mg, 3470 mg, 350 mg, 350 mg, 350 mg, 360 mg, 375 mg, 380 mg, 385 mg, 386 mg, 387 mg, 388 mg, 389 mg, 390 mg, 391 mg, 392 mg, 393 mg, 394 mg, 395 mg, 396 mg, 397 mg, 398 mg, 399 mg, 400 mg, 401 mg ,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2, 380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,48 0mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580 mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg , 2,690 mg, or 2,700 mg in a single dose (e.g., on the day of embryo transfer therapy), for example, in an amount of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0150] In some embodiments, the compound is administered in a single dose of about 1,600 mg to about 2,600 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,610 mg to about 2,590 mg, about 1,620 mg to about 2,580 mg, about 1,630 mg to about 2,570 mg, about 1,640 mg to about 2,560 mg, about 1,650 mg to about 2,550 mg, about 1,660 mg to about 2,540 mg, about 1,670 mg to about 2,530 mg, about 1,680 mg to about 2,520 mg, about 1,690 mg to about 2,510 mg, or about 1,700 mg to about 2,500 mg , about 1,710mg to about 2,490mg, about 1,720mg to about 2,480mg, about 1,730mg to about 2,470mg, about 1,740mg to about 2,460mg, about 1,750mg to about 2,450mg, about 1,760mg to about 2,440mg, about 1,770mg Approximately 2,430mg, approximately 1,780mg to approximately 2,420mg, approximately 1,790mg to approximately 2,410mg, approximately 1,800mg to approximately 2,400mg, approximately 1,810mg to approximately 2,390mg, approximately 1,820mg to approximately 2,380mg, approximately 1,830mg to approximately 2,370mg, approximately 1 ,840mg~about 2,360mg,about 1,850mg~about 2,350mg,about 1,860mg~about 2,340mg,about 1,870mg~about 2,330mg,about 1,880mg~about 2,320mg,about 1,890mg~about 2,310mg,about 1,900mg~about 2, 300mg, about 1,910mg to about 2,290mg, about 1,920mg to about 2,280mg, about 1,930mg to about 2,270mg, about 1,940mg to about 2,260mg, about 1,950mg to about 2,250mg, about 1,960mg to about 2,240mg, about 1,97 0 mg to about 2,230 mg, about 1,980 mg to about 2,220 mg, about 1,990 mg to about 2,210 mg, about 2,000 mg to about 2,200 mg, about 2,010 mg to about 2,190 mg, about 2,020 mg to about 2,180 mg, about 2,030 mg to about 2,170 mg, about 2,040 mg to about 2,160 mg, about 2,050 mg to about 2,150 mg, about 2,060 mg to about 2,140 mg, about 2,070 mg to about 2,130 mg, about 2,080 mg to about 2,120 mg, or about 2,090 mg to about 2,110 mg, for example, about 2,A single dose of 100 mg is administered to the subject (e.g., on the day of embryo transfer therapy), and the compound is, for example, (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0151] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 1,800 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0152] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 2,100 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0153] In some embodiments, the compound is administered to the subject (e.g., on the day of embryo transfer therapy) in a single dose of about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0154] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0155] In some embodiments of any of the above aspects of the present disclosure, administration of the oxytocin antagonist reduces the likelihood of embryo implantation failure and / or miscarriage.

[0156] In another aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound is administered in an amount of about 1,500 mg to about 2,700 mg per dose (e.g., about 1,500 mg to about 2,100 mg per dose, about 1,550 mg to about 2,050 mg per dose, about 1,600 mg to about 2,000 mg per dose, about 1,650 mg to about 1,950 mg per dose, about 1,700 mg to about 1,900 mg per dose, about 1,750 mg to about 1,850 mg per dose, about 1,760 mg to about 1,840 mg per dose, about 1,770 mg to about 1,830 mg per dose, about 1,780 mg to about 1,820 mg per dose, about 1,840 mg to about 1,850 mg per dose, about 1,850 mg to about 1,860 mg per dose, about 1,870 mg to about 1,880 mg per dose, about 1,890 mg to about 2,920 mg per dose, about 1,940 mg to about 2,950 mg per dose, about 1,960 mg to about 2,970 mg per dose, about 1,980 mg to about 2,990 mg per dose, about 1,990 mg to about 2,990 mg per dose, about 2,000 mg to about 2,0 ... 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg per dose, about 1,792 mg to about 1,808 mg per dose, about 1,793 mg to about 1,807 mg per dose, about 1,794 mg to about 1,806 mg per dose, about 1,795 mg to about 1,805 mg per dose, about 1,796 mg to about 1,804 mg per dose, about 1,797 mg to about 1,803 mg per dose, about 1,798 mg to about 1,802 mg per dose, or about 1,799 mg to about 1,801 mg per dose, for example about 1,500 mg per dose, 1,666 0mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820 mg, 1,830 mg, 1,840 mg, 1,850 mg, 1,860 mg, 1,870 mg, 1,880 mg, 1,890 mg, 1,900 mg, 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg, e.g., about 1,000 mg per dose.In an amount of 800 mg, or about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,408 mg per dose, about 2,410 mg to about 2,420 ... 393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose, for example, about 2,400 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)), and b. A method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject prior to administration of an oxytocin antagonist.

[0157] In another aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2 is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses) totaling about 1,500 mg to about 2,700 mg (e.g., totaling about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg). , about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, a total of 1,500 mg. 00mg, 1,510mg, 1,520mg, 1,530mg, 1,540mg, 1,550mg, 1,560mg, 1,570mg, 1,580mg, 1,590mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,6 50mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,750mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,80 0mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, 1,910mg, 1,920mg, 1,930mg, 1,940mg, 1,950mg, 1,960mg, 1,970mg, 1,980mg, 1,990mg, 2,000mg, 2,010mg, 2,020mg, 2,030mg, 2,040mg, 2,050mg, 2,060mg, 2,070mg, 2,080mg, 2,090mg, or 2,In one or more doses of 100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses of about 1,800 mg total (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), or in a total of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg , about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg to about 2,406 mg, about 2,395 mg to about 2,405 mg, about 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 7 , 10 or more doses), for example, a total of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530 mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,650mg, 2,660mg, 2,670mg, 2,680mg, 2,690 mg, or 2,700 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), for example, in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 2,400 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime) represented by Formula (II)); b. A method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject prior to administration of an oxytocin antagonist.

[0158] In a further aspect, the present disclosure provides a method for producing a pharmaceutical composition comprising: a. administering to a subject a therapeutically effective amount of an oxytocin antagonist, such as a compound represented by formula (I); [ka] or a geometric isomer, enantiomer, diastereomer, racemate, or salt thereof, In the formula, n is an integer of 1 to 3, R 1 is selected from the group consisting of hydrogen and C1-C6 alkyl; R 2is hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, heteroaryl, C1-C6 alkylheteroaryl, C2-C6 alkenyl, C2-C6 alkenylaryl, C2-C6 alkenylheteroaryl, C2-C6 alkynyl, C2-C6 alkynylaryl, C2-C6 alkynylheteroaryl, C3-C6 cycloalkyl, heterocycloalkyl, C1-C6 alkylcycloalkyl, C1-C6 alkylheterocycloalkyl, C1-C6 alkylcarboxy, acyl, C1-C6 alkylacyl, C1-C6 alkyl selected from the group consisting of acyloxy, C1-C6 alkylalkoxy, alkoxycarbonyl, C1-C6 alkylalkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 alkylacylamino, C1-C6 alkylureido, amino, C1-C6 alkylamino, sulfonyloxy, C1-C6 alkylsulfonyloxy, sulfonyl, C1-C6 alkylsulfonyl, sulfinyl, C1-C6 alkylsulfinyl, C1-C6 alkylsulfanyl, and C1-C6 alkylsulfonylamino; R 3 is selected from the group consisting of aryl and heteroaryl; X is oxygen and NR 4 is selected from the group consisting of R 4 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, aryl, and heteroaryl; R 2 and R 4 can, together with the nitrogen to which they are attached, form a 5- to 8-membered saturated or unsaturated heterocycloalkyl ring; The compound may be administered (e.g., on the day of embryo transfer therapy) in a single dose of about 1,500 mg to about 2,700 mg (e.g., about 1,500 mg to about 2,100 mg, about 1,550 mg to about 2,050 mg, about 1,600 mg to about 2,000 mg, about 1,650 mg to about 1,950 mg, about 1,700 mg to about 1,900 mg, about 1,750 mg to about 1,850 mg, about 1,760 mg to about 1,840 mg, about 1,770 mg to about 1,830 mg, about 1,780 mg to about 1,820 mg, about 1,790 mg to about 1,810 mg, about 1,791 mg to about 1,809 mg, about 1,810 mg to about 1,820 mg, about 1,830 mg to about 1,840 mg, about 1,850 mg to about 1,850 mg, about 1,860 mg to about 1,870 mg, about 1,880 mg to about 1,890 mg, about 1,891 mg to about 2,920 mg, about 1,892 mg to about 2,930 mg, about 1,893 mg to about 2,940 mg, about 1,894 mg to about 2,950 mg, about 1,895 mg to about 2,960 mg, about 1,895 mg to about 2,970 mg, about 1,895 mg to about 2,980 mg, about 1,895 mg to about 2,995 mg, about 2,995 mg to about 3,000 mg, about 2,000 mg to about 3,0 A single dose of 792 mg to about 1,808 mg, about 1,793 mg to about 1,807 mg, about 1,794 mg to about 1,806 mg, about 1,795 mg to about 1,805 mg, about 1,796 mg to about 1,804 mg, about 1,797 mg to about 1,803 mg, about 1,798 mg to about 1,802 mg, or about 1,799 mg to about 1,801 mg (e.g., on the day of embryo transfer therapy), e.g., about 1,500 mg, 1,510 mg, 1,520 mg, 1,530 mg, 1,540 mg, 1,550 mg, 1,560 mg, 1,570 mg, 1,580 mg, 1,590 mg, 1,600mg, 1,610mg, 1,620mg, 1,630mg, 1,640mg, 1,650mg, 1,660mg, 1,670mg, 1,680mg, 1,690mg, 1,700mg, 1,710mg, 1,720mg, 1,730mg, 1,740mg, 1,75 0mg, 1,760mg, 1,770mg, 1,780mg, 1,790mg, 1,800mg, 1,810mg, 1,820mg, 1,830mg, 1,840mg, 1,850mg, 1,860mg, 1,870mg, 1,880mg, 1,890mg, 1,900mg, In a single dose of 1,910 mg, 1,920 mg, 1,930 mg, 1,940 mg, 1,950 mg, 1,960 mg, 1,970 mg, 1,980 mg, 1,990 mg, 2,000 mg, 2,010 mg, 2,020 mg, 2,030 mg, 2,040 mg, 2,050 mg, 2,060 mg, 2,070 mg, 2,080 mg, 2,090 mg, or 2,100 mg (e.g., on the day of embryo transfer therapy), for example, in a single dose of about 1,800 mg (e.g., on the day of embryo transfer therapy), or about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,700 mg650mg, about 2,200mg to about 2,600mg, about 2,250mg to about 2,550mg, about 2,300mg to about 2,500mg, about 2,350mg to about 2,450mg, about 2,360mg to about 2,440mg, about 2,370mg to about 2,430mg, about 2,380mg Approximately 2,420mg, approximately 2,390mg to approximately 2,410mg, approximately 2,391mg to approximately 2,409mg, approximately 2,392mg to approximately 2,408mg, approximately 2,393mg to approximately 2,407mg, approximately 2,394mg to approximately 2,406mg, approximately 2,395mg to approximately 2,405mg, approximately 2,396 mg to about 2,404 mg, about 2,397 mg to about 2,403 mg, about 2,398 mg to about 2,402 mg, or about 2,399 mg to about 2,401 mg (e.g., on the day of embryo transfer therapy), e.g., about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,260 mg, 2,270 mg, 2,280 mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,4 40mg, 2,450mg, 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550mg, 2,560mg, 2,570mg, 2,580mg, 2,590m g, 2,600 mg, 2,610 mg, 2,620 mg, 2,630 mg, 2,640 mg, 2,650 mg, 2,660 mg, 2,670 mg, 2,680 mg, 2,690 mg, or 2,700 mg (e.g., on the day of embryo transfer therapy), for example, in an amount of about 2,400 mg to a subject (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)); b. A method of treating a subject undergoing embryo transfer therapy by transferring one or more embryos (e.g., one, two, three, or more embryos) into the uterus of the subject prior to administration of an oxytocin antagonist.

[0159] In another aspect, the disclosure features an oxytocin antagonist, such as a compound represented by Formula (I), for use in a method according to any of the preceding aspects of the disclosure.

[0160] In some embodiments of any of the above aspects of the present disclosure, the administration reduces the likelihood of embryo implantation failure and / or miscarriage.

[0161] In some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 24 hours after transfer of one or more embryos into the subject. For example, in some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 12 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 12 hours to about 24 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 10 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 9 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 8 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 7 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 6 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 5 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 1 hour to about 4 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 2 hours to about 6 hours after transfer of one or more embryos into the subject. In some embodiments, the oxytocin antagonist is administered to the subject within about 3 hours to about 5 hours after transfer of one or more embryos into the subject.

[0162] For example, in some embodiments, the oxytocin antagonist is administered to the subject about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or more, after transfer of one or more embryos into the subject.

[0163] In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in a single dose.

[0164] In some embodiments, the oxytocin antagonist is administered to the subject in multiple doses after embryo transfer, such as in multiple periodic doses, hi some embodiments, the oxytocin antagonist is administered to the subject in 1 to 20 doses after embryo transfer, for example, every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject at 1 to 20 doses every 24 hours after embryo transfer, such as 1 dose every 24 hours, 2 doses every 24 hours, 3 doses every 24 hours, 4 doses every 24 hours, 5 doses every 24 hours, 6 doses every 24 hours, 7 doses every 24 hours, 8 doses every 24 hours, 9 doses every 24 hours, 10 doses every 24 hours, 11 doses every 24 hours, 12 doses every 24 hours, 13 doses every 24 hours, 14 doses every 24 hours, 15 doses every 24 hours, 16 doses every 24 hours, 17 doses every 24 hours, 18 doses every 24 hours, 19 doses every 24 hours, or 20 doses every 24 hours. In some embodiments, the oxytocin antagonist is administered to the subject at more than 20 doses every 24 hours after embryo transfer.

[0165] For example, in some embodiments, the oxytocin antagonist is administered to the subject in 1 to 10 doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 1 to 10 doses every 24 hours, such as 1 dose every 24 hours, 2 doses every 24 hours, 3 doses every 24 hours, 4 doses every 24 hours, 5 doses every 24 hours, 6 doses every 24 hours, 7 doses every 24 hours, 8 doses every 24 hours, 9 doses every 24 hours, or 10 doses every 24 hours.

[0166] In some embodiments, the oxytocin antagonist is administered to the subject in 1 to 5 doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10 to 20 doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, after embryo transfer. In some embodiments, the oxytocin antagonist is administered to the subject in 10-15 doses, for example, every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, or longer, following embryo transfer.

[0167] In some embodiments, the oxytocin antagonist is administered to the subject in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more doses, e.g., every 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours or more after embryo transfer.

[0168] In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer at up to seven doses every 24 hours (e.g., 1, 2, 3, 4, 5, 6, or 7 doses). In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer at one dose every 24 hours, such as one dose every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer at two doses every 24 hours, such as two doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer at three doses every 24 hours, such as three doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer at four doses every 24 hours, such as four doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in five doses every 24 hours, such as five doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in six doses every 24 hours, such as six doses every 24 hours of Compound (II) below. In some embodiments, the oxytocin antagonist is administered to the subject after embryo transfer in seven doses every 24 hours, such as seven doses every 24 hours of Compound (II) below.

[0169] If the oxytocin antagonist is administered in multiple doses after embryo transfer, administration of the oxytocin antagonist may be terminated, for example, within about 1 hour to about 14 days, or longer, after embryo transfer. For example, administration of the oxytocin antagonist may be terminated within about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours, 132 hours, 144 hours, 156 hours, 168 hours, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days or more after embryo transfer.

[0170] Thus, in some embodiments, the oxytocin antagonist is administered to the subject in a daily dose from about 1 day to about 14 days after embryo transfer. In some embodiments, the daily dose is administered to the subject from about 3 days to about 11 days after embryo transfer. In some embodiments, the daily dose is administered to the subject for 7 days after embryo transfer.

[0171] In some embodiments, administering oxytocin antagonist to a subject reduces the possibility that the subject will have a miscarriage.For example, administering oxytocin antagonist can reduce the possibility that the subject will have a miscarriage after the process of embryo transfer, for example, at least about 24 weeks of gestation, so that the subject will give birth to a live baby (e.g., a live human infant).

[0172] In some embodiments, the oxytocin antagonist is administered to the subject in an amount sufficient to achieve a plasma concentration of the oxytocin antagonist in the subject of about 1 μM to about 20 μM. In some embodiments, the oxytocin antagonist is a compound represented by Formula (I) (e.g., a compound represented by Formula (II) herein) and is administered to the subject such that the subject exhibits a plasma concentration of the compound of about 1 μM to about 20 μM at the time of embryo transfer into the subject's uterus. For example, in some embodiments, the compound is administered to the subject in an amount sufficient to achieve a plasma concentration of the compound in the subject (e.g., at the time of embryo transfer) of about 5 μM to about 19 μM, 10 μM to about 18 μM, 14 μM to about 17 μM, 15 μM to about 16 μM, 1 μM to about 19 μM, 2 μM to about 18 μM, 3 μM to about 17 μM, 4 μM to about 16 μM, 5 μM to about 15 μM, or more. In some embodiments, the plasma concentration, such as the maximum plasma concentration achieved from administration of a single dose of the compound, is achieved within about 1 hour to about 3 hours (e.g., about 1 hour, 1.1 hours, 1.2 hours, 1.3 hours, 1.4 hours, 1.5 hours, 1.6 hours, 1.7 hours, 1.8 hours, 1.9 hours, 2 hours, 2.1 hours, 2.2 hours, 2.3 hours, 2.4 hours, 2.5 hours, 2.6 hours, 2.7 hours, 2.8 hours, 2.9 hours, or 3 hours) of administration of the compound to the subject.

[0173] In some embodiments, 1 to 3 embryos are implanted into the subject. In some embodiments, 1 to 2 embryos are implanted into the subject. For example, in some embodiments, 1 embryo is implanted into the subject. In some embodiments, 2 embryos are implanted into the subject. In some embodiments, 3 embryos are implanted into the subject.

[0174] In some embodiments, the subject has previously undergone one or more cycles (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more cycles) of unsuccessful embryo transfer therapy, such as by in vitro fertilization-embryo transfer (IVF-ET) or intracytoplasmic sperm injection-embryo transfer (ICSI-ET) therapy. In some embodiments, the subject has not previously undergone embryo transfer therapy.

[0175] In some embodiments, the subject is a mammal and the one or more embryos are mammalian embryos, e.g., in some embodiments, the mammal is a human and the one or more mammalian embryos are human embryos.

[0176] In some embodiments, the one or more embryos are produced in vitro by in vitro fertilization (IVF), such as by IVF of one or more eggs from the subject. In some embodiments, the one or more embryos are produced in vitro by intracytoplasmic sperm injection (ICSI), such as by ICSI into one or more eggs from the subject.

[0177] In some embodiments, the one or more eggs are derived from one or more oocytes (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more oocytes) isolated from a subject. In some embodiments, the one or more oocytes comprise 1 to 4 eggs (mature oocytes). For example, in some embodiments, the one or more oocytes comprise one mature oocyte. In some embodiments, the one or more oocytes comprise two mature oocytes. In some embodiments, the one or more oocytes comprise three mature oocytes. In some embodiments, the one or more oocytes comprise four mature oocytes.

[0178] In some embodiments, one or more oocytes are isolated directly from a subject.

[0179] In some embodiments, one or more oocytes or eggs are isolated from a subject about 1 to about 7 days prior to implantation of one or more embryos into a subject. In some embodiments, one or more oocytes or eggs are isolated from a subject about 2 to about 6 days prior to implantation of one or more embryos into a subject. In some embodiments, one or more oocytes or eggs are isolated from a subject about 3 to about 5 days prior to implantation of one or more embryos into a subject. In some embodiments, one or more oocytes or eggs are isolated from a subject about 3 days prior to implantation of one or more embryos into a subject. In some embodiments, one or more oocytes or eggs are isolated from a subject about 4 days prior to implantation of one or more embryos into a subject. In some embodiments, one or more oocytes or eggs are isolated from a subject about 5 days prior to implantation of one or more embryos into a subject.

[0180] In some embodiments, a gonadotropin-releasing hormone (GnRH) antagonist is administered to a subject before isolating one or more oocytes (e.g., including one or more mature oocytes) or eggs from the subject. In some embodiments, human chorionic gonadotropin (hCG) is administered to a subject before isolating one or more oocytes or eggs from the subject. For example, hCG can be administered to a subject in a single dose. In some embodiments, hCG is administered to a subject in multiple doses. hCG can be administered to a subject intravenously, such as by intravenous injection.

[0181] In some embodiments, progesterone is administered to a subject after isolation of one or more oocytes or eggs from the subject. Progesterone may be administered intravaginally and may range from about 300 mg to about 600 mg (e.g., about 300 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg, 480 mg, 485 mg, 490 mg, 500 mg, 505 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585 mg, 590 mg, 600 mg, 605 mg, 610 mg, 615 mg, 620 mg, 625 mg, 630 mg, 635 mg, 640 mg, 645 mg, 650 mg, 655 mg, 660 mg, 665 mg, 670 mg, 675 mg, 680 mg, 68 In some embodiments, progesterone may be administered at a dose of 300 mg per dose after isolation of one or more oocytes or eggs from the subject. In some embodiments, progesterone may be administered at a dose of 600 mg per dose after isolation of one or more oocytes or eggs from the subject. In some embodiments, progesterone is administered to the subject daily, preferably starting within about 24 hours (e.g., within about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours) of isolation of one or more oocytes or eggs from the subject and continuing for about six weeks or more (e.g., from about 6 weeks to about 10 weeks, such as about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, or more) after transfer of one or more embryos into the subject.

[0182] In some embodiments, the one or more embryos are freshly transferred into the subject's uterus (i.e., transferred into the subject's uterus during the same menstrual cycle as the isolation of one or more oocytes or eggs from the subject). For example, the one or more embryos may be transferred into the subject's uterus about 1 to about 7 days (e.g., about 3 to about 5 days, such as about 3, 4, or 5 days) after the isolation of one or more oocytes or eggs from the subject in preparation for IVF or ICSI.

[0183] In some embodiments, the one or more embryos are frozen and thawed prior to transfer of the one or more embryos to a subject.

[0184] In some embodiments, the one or more embryos each comprise 6-8 blastomeres immediately prior to transfer of the one or more embryos to a subject. The blastomeres may be approximately equal in size as assessed by visual microscopy prior to transfer of the one or more embryos to a subject. In some embodiments, the one or more embryos comprise an embryo having the morphology of a morula. In some embodiments, the one or more embryos comprise an embryo having the morphology of a blastula (e.g., a mammalian blastocyst).

[0185] In some embodiments, the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II). [ka]

[0186] In some embodiments, the compound represented by Formula (II) (i.e., (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime) is substantially pure. For example, in some embodiments, the compound represented by Formula (II) has a purity of at least 85%, such as 85% to 99.9% or greater (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or greater). The purity of the compound represented by Formula (II) can be assessed using, for example, chromatographic methods, such as nuclear magnetic resonance (NMR) techniques and / or high performance liquid chromatography (HPLC) procedures, which are well known in the art and described herein, such as those techniques described in U.S. Pat. No. 9,670,155, the disclosure of which is incorporated herein by reference in its entirety.

[0187] In some embodiments, the compound represented by Formula (II) is substantially pure with respect to its diastereomers and other by-products that may be formed during the synthesis of the compound. For example, in some embodiments, the compound represented by Formula (II) has a purity of at least 85%, such as 85% to 99.9% or greater (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or greater) with respect to its diastereomers and other by-products that may be formed during the synthesis of the compound, such as those formed during the synthesis of the compound described in U.S. Patent No. 9,670,155. The purity of the compound represented by Formula (II) can be assessed using, for example, chromatographic methods such as NMR techniques and / or HPLC procedures well known in the art and described herein, such as those techniques described in U.S. Pat. No. 9,670,155.

[0188] In some embodiments, the compound represented by Formula (II) is substantially pure with respect to its (3E) diastereomer, (3E,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime. For example, in some embodiments, the compound represented by Formula (II) has a purity of at least 85%, such as a purity of 85% to 99.9% or greater with respect to (3E,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime (e.g., a purity of 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or greater). For example, compound (II) can be administered in the form of a composition (e.g., a tablet, such as a dispersible tablet, a capsule, a gelcap, a powder, a liquid solution, or a liquid suspension) containing less than 15% of the (3E) diastereomer. For example, compound (II) can be administered in the form of a composition (e.g., a tablet, such as a dispersible tablet, a capsule, a gelcap, a powder, a liquid solution, or a liquid suspension) containing less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.1%, less than 0.01%, less than 0.001%, or less than 0.001% or less of the (3E) diastereomer. The purity of the compound represented by formula (II) can be assessed, for example, using chromatographic methods such as NMR techniques and / or HPLC procedures well known in the art and described herein, such as those described in U.S. Pat. No. 9,670,155.

[0189] In some embodiments, the compound is in a crystalline state. In some embodiments, the compound exhibits characteristic X-ray powder diffraction peaks at about 7.05°2θ, about 13.13°2θ, and about 23.34°2θ. For example, the compound may exhibit characteristic X-ray powder diffraction peaks at about 7.05°2θ, about 12.25°2θ, about 13.13°2θ, about 16.54°2θ, about 18.00°2θ, about 21.84°2θ, and about 23.34°2θ. In some embodiments, the compound exhibits characteristic X-ray powder diffraction peaks as shown in Table 1 below. [Table 1]

[0190] In some embodiments, the compound is administered to the subject orally. In some embodiments, the compound is administered to the subject intravenously. For example, the compound can be administered to the subject in the form of a tablet, capsule, gel cap, powder, liquid solution, or liquid suspension. In some embodiments, the compound is administered to the subject in the form of a tablet, such as a dispersible tablet. The dispersible tablet can have, for example, one or more or all of the following components: a. about 1-20% by weight of calcium silicate; b. about 0.1 to 20% by weight of PVP30K; c. about 0.01-5% by weight of poloxamer 188; d. about 0.5-20% by weight of croscarmellose sodium; e. about 1 to 90% by weight of microcrystalline cellulose 112; f. about 1 to 90% by weight of lactose monohydrate; g. about 0.01 to 0.5% by weight of sodium saccharin, and h. about 0.1-10% by weight of glycerol dibehenate.

[0191] For example, the dispersible tablet may have the following composition: a. about 5% by weight of calcium silicate; b. about 1% by weight of PVP30K; c. about 2% by weight of poloxamer 188; d. about 5% by weight of croscarmellose sodium; e. about 1.5% by weight of microcrystalline cellulose 112; f. about 47.8% by weight of lactose monohydrate; g. about 0.2% by weight of sodium saccharin, and h. about 4% by weight of glycerol dibehenate.

[0192] In some embodiments, the compound is administered at a concentration of about 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg The subject is administered a unit dosage form containing about 25 mg to about 250 mg of the compound, such as a unit dosage form containing 60 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, or more of the compound. In some embodiments, the subject is administered a unit dosage form containing about 25 mg to about 75 mg of the compound, such as a unit dosage form containing about 50 mg of the compound. In some embodiments, the subject is administered a unit dosage form containing about 175 mg to about 225 mg of the compound, such as a unit dosage form containing about 200 mg of the compound.

[0193] In some embodiments, the oxytocin antagonist is administered in an amount of 1,500 mg to 2,100 mg per dose, e.g., 1,510 mg to 2,090 mg per dose, 1,520 mg to 2,080 mg per dose, 1,530 mg to 2,070 mg per dose, 1,540 mg to 2,060 mg per dose, 1,550 mg to 2,050 mg per dose, 1,560 mg to 2,040 mg per dose, 1,570 mg to 2,030 mg per dose, 1,580 mg to 2,090 mg per dose, 1,590 mg to 2,100 mg per dose, 2,110 mg to 2,120 mg per dose, 2,130 mg to 2,140 mg per dose, 2,150 mg to 2,160 mg per dose, 2,170 mg to 2,180 mg per dose, 2,190 mg to 2,220 mg per dose, 2,230 mg to 2,240 mg per dose, 2,240 mg to 2,250 mg per dose, 2,250 mg to 2,260 mg per dose, 2,260 mg to 2,270 mg per dose, 2,270 mg to 2,280 mg per dose, 2,280 mg to 2,300 mg per dose, 2,310 mg to 2,320 mg per dose, 2,330 mg to 2,340 mg per dose, 2,350 mg to 2,360 mg per dose, 2,370 mg to 2,380 mg per dose, 2,390 mg to 2,400 mg per dose, 2,410 mg to 2,420 mg per dose, 2,4 0 mg, 1,580 mg to 2,020 mg per dose, 1,590 mg to 2,010 mg per dose, 1,600 mg to 2,000 mg per dose, 1,610 mg to 1,990 mg per dose, 1,620 mg to 1,980 mg per dose, 1,630 mg to 1,970 mg per dose, 1,640 mg to 1,960 mg per dose, 1,650 mg to 1,950 mg per dose, 1,660 mg to 1,940 mg per dose, 1,670mg to 1,930mg per dose, 1,680mg to 1,920mg per dose, 1,690mg to 1,910mg per dose, 1,700mg to 1,900mg per dose, 1,710mg to 1,890mg per dose, 1,720mg to 1,880mg per dose, 1,730mg to 1,870mg per dose, 1,740mg to 1,860mg per dose, 1,750mg to 1,850mg per dose, 1,760mg per dose The oxytocin antagonist is administered to a subject in an amount of 1,770 mg to 1,830 mg per dose, 1,780 mg to 1,820 mg per dose, or 1,790 mg to 1,810 mg per dose (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0194] For example, in some embodiments, the oxytocin antagonist is administered in an amount of about 1,501 mg to about 2,099 mg per dose, e.g., about 1,501 mg, 1,502 mg, 1,503 mg, 1,504 mg, 1,505 mg, 1,506 mg, 1,507 mg, 1,508 mg, 1,509 mg, 1,510 mg, 1,511 mg, 1,512 mg, 1,513 mg, 1,514 mg, 1,515 mg, 1,516 mg, 1,517 mg, 1,518 mg, 1,519 mg, 1,520 mg, 1,521 mg, 1,522 mg, 1,523 mg per dose. , 1,524mg, 1,525mg, 1,526mg, 1,527mg, 1,528mg, 1,529mg, 1,530mg, 1,531mg, 1,532mg, 1,533mg, 1,534mg, 1,535mg, 1,536mg, 1,537mg, 1,538mg, 1,5 39mg, 1,540mg, 1,541mg, 1,542mg, 1,543mg, 1,544mg, 1,545mg, 1,546mg, 1,547mg, 1,548mg, 1,549mg, 1,550mg, 1,551mg, 1,552mg, 1,553mg, 1,554mg, 1,555mg, 1,556mg, 1,557mg, 1,558mg, 1,559mg, 1,560mg, 1,561mg, 1,562mg, 1,563mg, 1,564mg, 1,565mg, 1,566mg, 1,567mg, 1,568mg, 1,569mg, 1,57 0mg, 1,571mg, 1,572mg, 1,573mg, 1,574mg, 1,575mg, 1,576mg, 1,577mg, 1,578mg, 1,579mg, 1,580mg, 1,581mg, 1,582mg, 1,583mg, 1,584mg, 1,585mg, 1 ,586mg, 1,587mg, 1,588mg, 1,589mg, 1,590mg, 1,591mg, 1,592mg, 1,593mg, 1,594mg, 1,595mg, 1,596mg, 1,597mg, 1,598mg, 1,599mg, 1,600mg, 1,601 mg, 1,602mg, 1,603mg, 1,604mg, 1,605mg, 1,606mg, 1,607mg, 1,608mg, 1,609mg, 1,610mg, 1,611mg, 1,612mg, 1,613mg, 1,614mg, 1,615mg, 1,616mg, 1,617mg、1,618mg、1,619mg、1,620mg、1,621mg、1,622mg、1,623mg、1,624mg、1,625mg、1,626mg、1,627mg、1,628mg、1,629mg、1,630mg、1,631mg、1,632mg、1,633mg、1,634mg、1,635mg、1,636mg、1,637mg、1,638mg、1,639mg、1,640mg、1,641mg、1,642mg、1,643mg、1,644mg、1,645mg、1,646mg、1,647mg、1,648mg、1,649mg、1,650mg、1,651mg、1,652mg、1,653mg、1,654mg、1,655mg、1,656mg、1,657mg、1,658mg、1,659mg、1,660mg、1,661mg、1,662mg、1,663mg、1,664mg、1,665mg、1,666mg、1,667mg、1,668mg、1,669mg、1,670mg、1,671mg、1,672mg、1,673mg、1,674mg、1,675mg、1,676mg、1,677mg、1,678mg、1,679mg、1,680mg、1,681mg、1,682mg、1,683mg、1,684mg、1,685mg、1,686mg、1,687mg、1,688mg、1,689mg、1,690mg、1,691mg、1,692mg、1,693mg、1,694mg、1,695mg、1,696mg、1,697mg、1,698mg、1,699mg、1,700mg、1,701mg、1,702mg、1,703mg、1,704mg、1,705mg、1,706mg、1,707mg、1,708mg、1,709mg、1,710mg、1,711mg、1,712mg、1,713mg、1,714mg、1,715mg、1,716mg、1,717mg、1,718mg、1,719mg、1,720mg、1,721mg、1,722mg、1,723mg、1,724mg、1,725mg、1,726mg、1,727mg、1,728mg、1,729mg、1,730mg、1,731mg、1,732mg、1,733mg、1,734mg、1,735mg、1,736mg、1,737mg、1,738mg、1,739mg、1,740mg、1,741mg、1,742mg、1,743mg、1,744mg、1,745mg、1,746mg、1,747mg、1,748mg、1,749mg、1,750mg、1,751mg、1,752mg、1,753mg、1,754mg、1,755mg、1,756mg、1,757mg、1,758mg、1,759mg、1,760mg、1,761mg、1,762mg、1,763mg、1,764mg、1,765mg、1,766mg、1,767mg、1,768mg、1,769mg、1,770mg、1,771mg、1,772mg、1,773mg、1,774mg、1,775mg、1,776mg、1,777mg、1,778mg、1,779mg、1,780mg、1,781mg、1,782mg、1,783mg、1,784mg、1,785mg、1,786mg、1,787mg、1,788mg、1,789mg、1,790mg、1,791mg、1,792mg、1,793mg、1,794mg、1,795mg、1,796mg、1,797mg、1,798mg、1,799mg、1,800mg、1,801mg、1,802mg、1,803mg、1,804mg、1,805mg、1,806mg、1,807mg、1,808mg、1,809mg、1,810mg、1,811mg、1,812mg、1,813mg、1,814mg、1,815mg、1,816mg、1,817mg、1,818mg、1,819mg、1,820mg、1,821mg、1,822mg、1,823mg、1,824mg、1,825mg、1,826mg、1,827mg、1,828mg、1,829mg、1,830mg、1,831mg、1,832mg、1,833mg、1,834mg、1,835mg、1,836mg、1,837mg、1,838mg、1,839mg、1,840mg、1,841mg、1,842mg、1,843mg、1,844mg、1,845mg、1,846mg、1,847mg、1,848mg、1,849mg、1,850mg、1,851mg、1,852mg、1,853mg、1,854mg、1,855mg、1,856mg、1,857mg、1,858mg、1,859mg、1,860mg、1,861mg、1,862mg、1,863mg、1,864mg、1,865mg、1,866mg、1,867mg、1,868mg、1,869mg、1,870mg、1,871mg、1,872mg、1,873mg、1,874mg、 1,875mg、1,876mg、1,877mg、1,878mg、1,879mg、1,880mg、1,881mg、1,882mg 、1,883mg、1,884mg、1,885mg、1,886mg、1,887mg、1,888mg、1,889mg、1,890 mg、1,891mg、1,892mg、1,893mg、1,894mg、1,895mg、1,896mg、1,897mg、1.89 8mg、1,899mg、1,900mg、1,901mg、1,902mg、1,903mg、1,904mg、1,905mg、1, 906mg、1,907mg、1,908mg、1,909mg、1,910mg、1,911mg、1,912mg、1,913mg、1 ,914mg、1,915mg、1,916mg、1,917mg、1,918mg、1,919mg、1,920mg、1,921mg、1,922mg、1,923mg、1,924mg、1,925mg、1,926mg、1,927mg、1,928mg、1,929m g、1,930mg、1,931mg、1,932mg、1,933mg、1,934mg、1,935mg、1,936mg、1.93 7mg、1,938mg、1,939mg、1,940mg、1,941mg、1,942mg、1,943mg、1,944mg、1,9 45mg、1,946mg、1,947mg、1,948mg、1,949mg、1,950mg、1,951mg、1,952mg、1,953mg、1,954mg、1,955mg、1,956mg、1,957mg、1,958mg、1,959mg、1,960mg、 1,961mg、1,962mg、1,963mg、1,964mg、1,965mg、1,966mg、1,967mg、1,968mg、1,969mg、1,970mg、1,971mg、1,972mg、1,973mg、1,974mg、1,975mg、1,976 mg、1,977mg、1,978mg、1,979mg、1,980mg、1,981mg、1,982mg、1,983mg、1,9 84mg、1,985mg、1,986mg、1,987mg、1,988mg、1,989mg、1,990mg、1,991mg、1,992mg, 1,993mg, 1,994mg, 1,995mg, 1,996mg, 1,997mg, 1,998mg, 1,999mg, 2,000mg, 2,001mg, 2,002mg, 2,003mg, 2,004mg, 2,005mg, 2,006mg, 2,007 mg, 2,008mg, 2,009mg, 2,010mg, 2,011mg, 2,012mg, 2,013mg, 2,014mg, 2,015mg, 2,016mg, 2,017mg, 2,018mg, 2,019mg, 2,020mg, 2,021mg, 2,022mg, 2,023mg, 2,024mg, 2,025mg, 2,026mg, 2,027mg, 2,028mg, 2,029mg, 2,030mg, 2,031mg, 2,032mg, 2,033mg, 2,034mg, 2,035mg, 2,036mg, 2,037mg, 2,0 38mg, 2,039mg, 2,040mg, 2,041mg, 2,042mg, 2,043mg, 2,044mg, 2,045mg, 2,046mg, 2,047mg, 2,048mg, 2,049mg, 2,050mg, 2,051mg, 2,052mg, 2,053mg , 2,054mg, 2,055mg, 2,056mg, 2,057mg, 2,058mg, 2,059mg, 2,060mg, 2,061mg, 2,062mg, 2,063mg, 2,064mg, 2,065mg, 2,066mg, 2,067mg, 2,068mg, 2, 069mg, 2,070mg, 2,071mg, 2,072mg, 2,073mg, 2,074mg, 2,075mg, 2,076mg, 2,077mg, 2,078mg, 2,079mg, 2,080mg, 2,081mg, 2,082mg, 2,083mg, 2,084 The oxytocin antagonist is administered to a subject in an amount of 2,085 mg, 2,086 mg, 2,087 mg, 2,088 mg, 2,089 mg, 2,090 mg, 2,091 mg, 2,092 mg, 2,093 mg, 2,094 mg, 2,095 mg, 2,096 mg, 2,097 mg, 2,098 mg, or 2,099 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0195] For example, in some embodiments, the oxytocin antagonist is administered in an amount of about 1,600 mg to about 2,000 mg per dose, e.g., about 1,600 mg, 1,601 mg, 1,602 mg, 1,603 mg, 1,604 mg, 1,605 mg, 1,606 mg, 1,607 mg, 1,608 mg, 1,609 mg, 1,610 mg, 1,611 mg, 1,612 mg, 1,613 mg, 1,614 mg, 1,615 mg, 1,616 mg, 1,617 mg, 1,618 mg, 1,619 mg, 1,620 mg, 1,621 mg, 1,622 mg per dose. , 1,623mg, 1,624mg, 1,625mg, 1,626mg, 1,627mg, 1,628mg, 1,629mg, 1,630mg, 1,631mg, 1,632mg, 1,633mg, 1,634mg, 1,635mg, 1,636mg, 1,637mg, 1,6 38mg, 1,639mg, 1,640mg, 1,641mg, 1,642mg, 1,643mg, 1,644mg, 1,645mg, 1,646mg, 1,647mg, 1,648mg, 1,649mg, 1,650mg, 1,651mg, 1,652mg, 1,653mg, 1,654mg, 1,655mg, 1,656mg, 1,657mg, 1,658mg, 1,659mg, 1,660mg, 1,661mg, 1,662mg, 1,663mg, 1,664mg, 1,665mg, 1,666mg, 1,667mg, 1,668mg, 1,66 9mg, 1,670mg, 1,671mg, 1,672mg, 1,673mg, 1,674mg, 1,675mg, 1,676mg, 1,677mg, 1,678mg, 1,679mg, 1,680mg, 1,681mg, 1,682mg, 1,683mg, 1,684mg, 1 ,685mg, 1,686mg, 1,687mg, 1,688mg, 1,689mg, 1,690mg, 1,691mg, 1,692mg, 1,693mg, 1,694mg, 1,695mg, 1,696mg, 1,697mg, 1,698mg, 1,699mg, 1,700 mg, 1,701mg, 1,702mg, 1,703mg, 1,704mg, 1,705mg, 1,706mg, 1,707mg, 1,708mg, 1,709mg, 1,710mg, 1,711mg, 1,712mg, 1,713mg, 1,714mg, 1,715mg, 1,716mg、1,717mg、1,718mg、1,719mg、1,720mg、1,721mg、1,722mg、1,723mg、1,724mg、1,725mg、1,726mg、1,727mg、1,728mg、1,729mg、1,730mg、1,731mg 、1,732mg、1,733mg、1,734mg、1,735mg、1,736mg、1,737mg、1,738mg、1,739mg、1,740mg、1,741mg、1,742mg、1,743mg、1,744mg、1,745mg、1,746mg、1,74 7mg、1,748mg、1,749mg、1,750mg、1,751mg、1,752mg、1,753mg、1,754mg、1,755mg、1,756mg、1,757mg、1,758mg、1,759mg、1,760mg、1,761mg、1,762mg、1 ,763mg、1,764mg、1,765mg、1,766mg、1,767mg、1,768mg、1,769mg、1,770mg、1,771mg、1,772mg、1,773mg、1,774mg、1,775mg、1,776mg、1,777mg、1,778m g、1,779mg、1,780mg、1,781mg、1,782mg、1,783mg、1,784mg、1,785mg、1,786mg、1,787mg、1,788mg、1,789mg、1,790mg、1,791mg、1,792mg、1,793mg、1,7 94mg、1,795mg、1,796mg、1,797mg、1,798mg、1,799mg、1,800mg、1,801mg、1 ,802mg、1,803mg、1,804mg、1,805mg、1,806mg、1,807mg、1,808mg、1,809mg、 1,810mg、1,811mg、1,812mg、1,813mg、1,814mg、1,815mg、1,816mg、1,817m g、1,818mg、1,819mg、1,820mg、1,821mg、1,822mg、1,823mg、1,824mg、1,825 mg、1,826mg、1,827mg、1,828mg、1,829mg、1,830mg、1,831mg、1,832mg、1,8 33mg、1,834mg、1,835mg、1,836mg、1,837mg、1,838mg、1,839mg、1,840mg、1,841mg、1,842mg、1,843mg、1,844mg、1,845mg、1,846mg、1,847mg、1,848mg、1,849mg、1,850mg、1,851mg、1,852mg、1,853mg、1,854mg、1,855mg、1,856mg、1,857mg、1,858mg、1,859mg、1,860mg、1,861mg、1,862mg、1,863mg、1,864mg、1,865mg、1,866mg、1,867mg、1,868mg、1,869mg、1,870mg、1,871mg、1,872mg、1,873mg、1,874mg、1,875mg、1,876mg、1,877mg、1,878mg、1,879mg、1,880mg、1,881mg、1,882mg、1,883mg、1,884mg、1,885mg、1,886mg、1,887mg、1,888mg、1,889mg、1,890mg、1,891mg、1,892mg、1,893mg、1,894mg、1,895mg、1,896mg、1,897mg、1,898mg、1,899mg、1,900mg、1,901mg、1,902mg、1,903mg、1,904mg、1,905mg、1,906mg、1,907mg、1,908mg、1,909mg、1,910mg、1,911mg、1,912mg、1,913mg、1,914mg、1,915mg、1,916mg、1,917mg、1,918mg、1,919mg、1,920mg、1,921mg、1,922mg、1,923mg、1,924mg、1,925mg、1,926mg、1,927mg、1,928mg、1,929mg、1,930mg、1,931mg、1,932mg、1,933mg、1,934mg、1,935mg、1,936mg、1,937mg、1,938mg、1,939mg、1,940mg、1,941mg、1,942mg、1,943mg、1,944mg、1,945mg、1,946mg、1,947mg、1,948mg、1,949mg、1,950mg、1,951mg、1,952mg、1,953mg、1,954mg、1,955mg、1,956mg、1,957mg、1,958mg、1,959mg、1,960mg、1,961mg、1,962mg、1,963mg、1,964mg、1,965mg、1,966mg, 1,967mg, 1,968mg, 1,969mg, 1,970mg, 1,971mg, 1,972mg, 1,973mg, 1,974mg, 1,975mg, 1,976mg, 1,977mg, 1,978m g, 1,979mg, 1,980mg, 1,981mg, 1,982mg, 1,983mg, 1,984mg, 1,985mg, 1,986mg, 1,987mg, 1,988mg, 1,989mg, 1,990mg, 1,9 The oxytocin antagonist is administered to a subject in an amount of 91 mg, 1,992 mg, 1,993 mg, 1,994 mg, 1,995 mg, 1,996 mg, 1,997 mg, 1,998 mg, 1,999 mg, or 2,000 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0196] For example, in some embodiments, the oxytocin antagonist is administered in an amount of about 1,700 mg to about 1,900 mg per dose, e.g., about 1,700 mg, 1,701 mg, 1,702 mg, 1,703 mg, 1,704 mg, 1,705 mg, 1,706 mg, 1,707 mg, 1,708 mg, 1,709 mg, 1,710 mg, 1,711 mg, 1,712 mg, 1,713 mg, 1,714 mg, 1,715 mg, 1,716 mg, 1,717 mg, 1,718 mg, 1,719 mg, 1,720 mg, 1,721 mg, 1,722 mg per dose. , 1,723mg, 1,724mg, 1,725mg, 1,726mg, 1,727mg, 1,728mg, 1,729mg, 1,730mg, 1,731mg, 1,732mg, 1,733mg, 1,734mg, 1,735mg, 1,736mg, 1,737mg, 1,7 38mg, 1,739mg, 1,740mg, 1,741mg, 1,742mg, 1,743mg, 1,744mg, 1,745mg, 1,746mg, 1,747mg, 1,748mg, 1,749mg, 1,750mg, 1,751mg, 1,752mg, 1,753mg, 1,754mg, 1,755mg, 1,756mg, 1,757mg, 1,758mg, 1,759mg, 1,760mg, 1,761mg, 1,762mg, 1,763mg, 1,764mg, 1,765mg, 1,766mg, 1,767mg, 1,768mg, 1,76 9mg, 1,770mg, 1,771mg, 1,772mg, 1,773mg, 1,774mg, 1,775mg, 1,776mg, 1,777mg, 1,778mg, 1,779mg, 1,780mg, 1,781mg, 1,782mg, 1,783mg, 1,784mg, 1 ,785mg, 1,786mg, 1,787mg, 1,788mg, 1,789mg, 1,790mg, 1,791mg, 1,792mg, 1,793mg, 1,794mg, 1,795mg, 1,796mg, 1,797mg, 1,798mg, 1,799mg, 1,800 mg, 1,801mg, 1,802mg, 1,803mg, 1,804mg, 1,805mg, 1,806mg, 1,807mg, 1,808mg, 1,809mg, 1,810mg, 1,811mg, 1,812mg, 1,813mg, 1,814mg, 1,815mg, 1,816mg, 1,817mg, 1,818mg, 1,819mg, 1,820mg, 1,821mg, 1,822mg, 1,823mg, 1,824mg, 1,825mg, 1,826mg, 1,827mg, 1,828m g, 1,829mg, 1,830mg, 1,831mg, 1,832mg, 1,833mg, 1,834mg, 1,835mg, 1,836mg, 1,837mg, 1,838mg, 1,839mg, 1,840mg, 1, 841mg, 1,842mg, 1,843mg, 1,844mg, 1,845mg, 1,846mg, 1,847mg, 1,848mg, 1,849mg, 1,850mg, 1,851mg, 1,852mg, 1,853m g, 1,854mg, 1,855mg, 1,856mg, 1,857mg, 1,858mg, 1,859mg, 1,860mg, 1,861mg, 1,862mg, 1,863mg, 1,864mg, 1,865mg, 1,8 66mg, 1,867mg, 1,868mg, 1,869mg, 1,870mg, 1,871mg, 1,872mg, 1,873mg, 1,874mg, 1,875mg, 1,876mg, 1,877mg, 1,878mg , 1,879mg, 1,880mg, 1,881mg, 1,882mg, 1,883mg, 1,884mg, 1,885mg, 1,886mg, 1,887mg, 1,888mg, 1,889mg, 1,890mg, 1,8 The oxytocin antagonist is administered to a subject in an amount of 91 mg, 1,892 mg, 1,893 mg, 1,894 mg, 1,895 mg, 1,896 mg, 1,897 mg, 1,898 mg, 1,899 mg, or 1,900 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0197] For example, in some embodiments, the oxytocin antagonist is administered in an amount of about 1,750 mg to about 1,850 mg per dose, e.g., about 1,750 mg, 1,751 mg, 1,752 mg, 1,753 mg, 1,754 mg, 1,755 mg, 1,756 mg, 1,757 mg, 1,758 mg, 1,759 mg, 1,760 mg, 1,761 mg, 1,762 mg, 1,763 mg, 1,764 mg, 1,765 mg, 1,766 mg, 1,767 mg, 1,768 mg, 1,769 mg, 1,770 mg, 1,771 mg, 1,772 mg, 1,773mg, 1,774mg, 1,775mg, 1,776mg, 1,777mg, 1,778mg, 1,779mg, 1,780mg, 1,781mg, 1,782mg, 1,783mg, 1,784mg, 1,785mg, 1,786mg, 1,787mg, 1,78 8mg, 1,789mg, 1,790mg, 1,791mg, 1,792mg, 1,793mg, 1,794mg, 1,795mg, 1,796mg, 1,797mg, 1,798mg, 1,799mg, 1,800mg, 1,801mg, 1,802mg, 1,803mg, 1 ,804mg, 1,805mg, 1,806mg, 1,807mg, 1,808mg, 1,809mg, 1,810mg, 1,811mg, 1,812mg, 1,813mg, 1,814mg, 1,815mg, 1,816mg, 1,817mg, 1,818mg, 1,819 mg, 1,820mg, 1,821mg, 1,822mg, 1,823mg, 1,824mg, 1,825mg, 1,826mg, 1,827mg, 1,828mg, 1,829mg, 1,830mg, 1,831mg, 1,832mg, 1,833mg, 1,834mg, 1, The oxytocin antagonist is administered to a subject in an amount of 835 mg, 1,836 mg, 1,837 mg, 1,838 mg, 1,839 mg, 1,840 mg, 1,841 mg, 1,842 mg, 1,843 mg, 1,844 mg, 1,845 mg, 1,846 mg, 1,847 mg, 1,848 mg, 1,849 mg, or 1,850 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0198] For example, in some embodiments, the oxytocin antagonist is administered in an amount of about 1,760 mg to about 1,840 mg per dose, e.g., about 1,760 mg, 1,761 mg, 1,762 mg, 1,763 mg, 1,764 mg, 1,765 mg, 1,766 mg, 1,767 mg, 1,768 mg, 1,769 mg, 1,770 mg, 1,771 mg, 1,772 mg, 1,773 mg, 1,774 mg, 1,775 mg, 1,776 mg, 1,777 mg per dose. , 1,778mg, 1,779mg, 1,780mg, 1,781mg, 1,782mg, 1,783mg, 1,784mg, 1,785mg, 1,786mg, 1,787mg, 1,788mg, 1,789mg, 1,790mg, 1,791mg, 1,792mg, 1,793mg, 1,794mg, 1,795mg, 1,796mg, 1,797mg, 1,798mg, 1,799mg, 1,800mg, 1,801mg, 1,802mg, 1,803mg, 1 ,804mg, 1,805mg, 1,806mg, 1,807mg, 1,808mg, 1,809mg, 1,810mg, 1,811mg, 1,812mg, 1,813mg, 1,814mg, 1,815mg, 1,816mg, 1 ,817mg, 1,818mg, 1,819mg, 1,820mg, 1,821mg, 1,822mg, 1,823mg, 1,824mg, 1,825mg, 1,826mg, 1,827mg, 1,828mg, 1,829mg, 1, The oxytocin antagonist is administered to a subject in an amount of 830 mg, 1,831 mg, 1,832 mg, 1,833 mg, 1,834 mg, 1,835 mg, 1,836 mg, 1,837 mg, 1,838 mg, 1,839 mg, or 1,840 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0199] For example, in some embodiments, the oxytocin antagonist is administered in an amount of about 1,770 mg to about 1,830 mg per dose, e.g., about 1,770 mg, 1,771 mg, 1,772 mg, 1,773 mg, 1,774 mg, 1,775 mg, 1,776 mg, 1,777 mg, 1,778 mg, 1,779 mg, 1,780 mg, 1,781 mg, 1,782 mg per dose. , 1,783mg, 1,784mg, 1,785mg, 1,786mg, 1,787mg, 1,788mg, 1,789mg, 1,790mg, 1,791mg, 1,792mg, 1,79 3mg, 1,794mg, 1,795mg, 1,796mg, 1,797mg, 1,798mg, 1,799mg, 1,800mg, 1,801mg, 1,802mg, 1,803mg, 1 ,804mg, 1,805mg, 1,806mg, 1,807mg, 1,808mg, 1,809mg, 1,810mg, 1,811mg, 1,812mg, 1,813mg, 1,814 mg, 1,815mg, 1,816mg, 1,817mg, 1,818mg, 1,819mg, 1,820mg, 1,821mg, 1,822mg, 1,823mg, 1,824mg, 1, The oxytocin antagonist is administered to a subject in an amount of 825 mg, 1,826 mg, 1,827 mg, 1,828 mg, 1,829 mg, or 1,830 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0200] For example, in some embodiments, the oxytocin antagonist is administered in an amount of about 1,780 mg to about 1,820 mg per dose, e.g., about 1,780 mg, 1,781 mg, 1,782 mg, 1,783 mg, 1,784 mg, 1,785 mg, 1,786 mg, 1,787 mg, 1,788 mg, 1,789 mg, 1,790 mg, 1,791 mg, 1,792 mg, 1,793 mg, 1,794 mg, 1,795 mg, 1,796 mg, 1,797 mg, 1,798 mg, 1,799 mg, 1,800 mg, 1,801 mg, 1,802 mg, 1,803 mg, 1,804 mg, 1,805 mg, 1,806 mg, 1,807 mg, 1,808 mg, 1,809 mg, 1,910 mg, 1,911 mg, 1,912 mg, 1,913 mg, 1,914 mg, 1,915 mg, 1,916 mg, 1,917 mg, 1,918 mg, 1,919 mg, 1,920 mg, 1,921 mg, 1,922 mg, 1,923 mg, 1,924 mg, 1,925 mg, 1,926 mg, 1,927 mg, 1,928 mg, 1,929 mg, 1,930 mg, 1,931 mg, 1,932 mg, 1,933 mg, 1,934 mg, 1,935 mg, 1,936 mg, 1,937 mg, 1 The oxytocin antagonist is administered to a subject in an amount of 1,804 mg, 1,805 mg, 1,806 mg, 1,807 mg, 1,808 mg, 1,809 mg, 1,810 mg, 1,811 mg, 1,812 mg, 1,813 mg, 1,814 mg, 1,815 mg, 1,816 mg, 1,817 mg, 1,818 mg, 1,819 mg, or 1,820 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0201] For example, in some embodiments, the oxytocin antagonist is administered in an amount of about 1,790 mg to about 1,810 mg per dose, e.g., about 1,790 mg, 1,791 mg, 1,792 mg, 1,793 mg, 1,794 mg, 1,795 mg, 1,796 mg, 1,797 mg, 1,798 mg, 1,799 mg, 1,800 mg, 1,801 mg, 1,802 mg, 1,803 mg, 1,804 mg, 1,805 mg, 1,806 mg, 1,807 mg, 1,808 mg, 1,809 mg, 1,910 mg, 1,911 mg, 1,912 mg, 1,913 mg, 1,914 mg, 1,915 mg, 1,916 mg, 1,917 mg, 1,918 mg, 1,919 mg, 1,920 mg, 1,921 mg, 1,922 mg, 1,923 mg, 1,924 mg, 1,925 mg, 1,926 mg, 1,927 mg, 1,928 mg, 1,929 mg, 1,930 mg, 1,931 mg, 1,932 mg, 1,933 mg, 1,934 mg, 1,935 mg, 1,936 mg, 1,937 mg, 1,938 mg, 1,940 mg, 1,941 mg, 1,942 mg, 1,943 mg, 1,944 mg, 1,945 mg, 1,946 mg, 1,947 mg, 1,948 mg, 1 The oxytocin antagonist is administered to a subject in an amount of 1,804 mg, 1,805 mg, 1,806 mg, 1,807 mg, 1,808 mg, 1,809 mg, or 1,810 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0202] In some embodiments, the compound is administered at a dose of about 2,100 mg to about 2,700 mg per dose, about 2,150 mg to about 2,650 mg per dose, about 2,200 mg to about 2,600 mg per dose, about 2,250 mg to about 2,550 mg per dose, about 2,300 mg to about 2,500 mg per dose, about 2,350 mg to about 2,450 mg per dose, about 2,360 mg to about 2,440 mg per dose, about 2,370 mg to about 2,430 mg per dose, about 2,380 mg to about 2,420 mg per dose, about 2,390 mg to about 2,410 mg per dose, about 2,391 mg to about 2,409 mg per dose, about 2,392 mg to about 2,450 mg per dose, about 2,450 mg to about 2,460 mg per dose, about 2,460 mg to about 2,470 mg per dose, about 2,470 mg to about 2,480 mg per dose, about 2,480 mg to about 2,490 mg per dose, about 2,491 mg to about 2,492 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,492 mg to about 3,500 mg per dose, about 2,50 ... The compound is administered to a subject in an amount of about 2,408 mg, about 2,393 mg to about 2,407 mg per dose, about 2,394 mg to about 2,406 mg per dose, about 2,395 mg to about 2,405 mg per dose, about 2,396 mg to about 2,404 mg per dose, about 2,397 mg to about 2,403 mg per dose, about 2,398 mg to about 2,402 mg per dose, or about 2,399 mg to about 2,401 mg per dose (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by Formula (II)).

[0203] For example, in some embodiments, the compound may be administered in an amount of about 2,100 mg, 2,110 mg, 2,120 mg, 2,130 mg, 2,140 mg, 2,150 mg, 2,160 mg, 2,170 mg, 2,180 mg, 2,190 mg, 2,200 mg, 2,210 mg, 2,220 mg, 2,230 mg, 2,240 mg, 2,250 mg, 2,300 mg, 2,310 mg, 2,320 mg, 2,330 mg, 2,340 mg, 2,350 mg, 2,360 mg, 2,370 mg, 2,380 mg, 2,390 mg, 2,400 mg, 2,410 mg, 2,420 mg, 2,430 260mg, 2,270mg, 2,280mg, 2,290mg, 2,300mg, 2,310mg, 2,320mg, 2,330mg, 2,340mg, 2,350mg, 2,360mg, 2,370mg, 2,380mg, 2,390mg, 2,400mg, 2,410mg, 2,420mg, 2,430mg, 2,440mg, 2,450mg , 2,460mg, 2,470mg, 2,480mg, 2,490mg, 2,500mg, 2,510mg, 2,520mg, 2,530mg, 2,540mg, 2,550 mg, 2,560mg, 2,570mg, 2,580mg, 2,590mg, 2,600mg, 2,610mg, 2,620mg, 2,630mg, 2,640mg, 2,65 The compound is administered to a subject in an amount of 0 mg, 2,660 mg, 2,670 mg, 2,680 mg, 2,690 mg, or 2,700 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0204] In some embodiments, the oxytocin antagonist is administered to the subject in an amount of about 1,800 mg per dose (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0205] In some embodiments, the oxytocin antagonist is administered to the subject in an amount of about 2,100 mg per dose (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II).

[0206] In some embodiments, the oxytocin antagonist is administered to the subject in an amount of about 2,400 mg per dose (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0207] In some embodiments, the oxytocin antagonist is administered in one or more doses totaling 1,500 mg to 2,100 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses), e.g., a total of 1,510 mg to 2,090 mg, 1,520 mg to 2,080 mg, 1,530 mg to 2,070 mg, 1,540 mg to 2,060 mg, 1,550 mg to 2,050 mg, 1,560 mg to 1,570 mg, 1,580 mg to 1,590 mg, 1,600 mg to 1,610 mg, 1,620 mg to 1,630 mg, 1,640 mg to 1,650 mg, 1,660 mg to 1,670 mg, 1,680 mg to 1,690 mg, 1,700 mg to 1,710 mg, 1,720 mg to 1,730 mg, 1,740 mg to 1,750 mg, 1,760 mg to 1,770 mg, 1,780 mg to 1,790 mg, 1,800 mg to 1,810 mg, 1,820 mg to 1,830 mg, 1,840 mg to 1,850 mg, 1,860 mg to 1,870 mg, 1,880 mg to 1,890 mg, 1,900 mg to 1,910 mg, 1,920 mg to 1,930 mg, 1,940 mg to 1,950 mg, 1,960 mg to 1,970 mg, 1,980 mg to 1 60mg~2,040mg, 1,570mg~2,030mg, 1,580mg~2,020mg, 1,590mg~2,010mg, 1,600mg~2,000mg, 1,610mg~1,990mg , 1,620mg~1,980mg, 1,630mg~1,970mg, 1,640mg~1,960mg, 1,650mg~1,950mg, 1,660mg~1,940mg, 1,670mg~1,9 30mg, 1,680mg to 1,920mg, 1,690mg to 1,910mg, 1,700mg to 1,900mg, 1,710mg to 1,890mg, 1,720mg to 1,880mg, 1,730mg to 1,870mg, 1,740mg to 1,860mg, 1,750mg to 1,850mg, 1,760mg to 1,840mg, 1,770mg to 1,830mg, 1,780mg to 1,820mg, or is administered to the subject in one or more doses of 1,790 mg to 1,810 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, represented by formula (II):

[0208] For example, in some embodiments, the oxytocin antagonist is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,501 mg to about 2,099 mg, e.g., a total of about 1,501 mg, 1,502 mg, 1,503 mg, 1,504 mg, 1,505 mg, 1,506 mg, 1,507 mg, 1,508 mg, 1,509 mg, 1,510 mg, 1,511 mg, 1,512 mg, 1,513 mg, 1,514 mg, 1,515 mg, 1,516 mg, 1,517 mg, 1,518 mg, g, 1,519mg, 1,520mg, 1,521mg, 1,522mg, 1,523mg, 1,524mg, 1,525mg, 1,526mg, 1,527mg, 1,528mg, 1,529mg, 1,530mg, 1,531mg, 1,532mg, 1,533mg, 1, 534mg, 1,535mg, 1,536mg, 1,537mg, 1,538mg, 1,539mg, 1,540mg, 1,541mg, 1,542mg, 1,543mg, 1,544mg, 1,545mg, 1,546mg, 1,547mg, 1,548mg, 1,549mg , 1,550mg, 1,551mg, 1,552mg, 1,553mg, 1,554mg, 1,555mg, 1,556mg, 1,557mg, 1,558mg, 1,559mg, 1,560mg, 1,561mg, 1,562mg, 1,563mg, 1,564mg, 1,5 65mg, 1,566mg, 1,567mg, 1,568mg, 1,569mg, 1,570mg, 1,571mg, 1,572mg, 1,573mg, 1,574mg, 1,575mg, 1,576mg, 1,577mg, 1,578mg, 1,579mg, 1,580mg, 1,581mg, 1,582mg, 1,583mg, 1,584mg, 1,585mg, 1,586mg, 1,587mg, 1,588mg, 1,589mg, 1,590mg, 1,591mg, 1,592mg, 1,593mg, 1,594mg, 1,595mg, 1,596 mg, 1,597mg, 1,598mg, 1,599mg, 1,600mg, 1,601mg, 1,602mg, 1,603mg, 1,604mg, 1,605mg, 1,606mg, 1,607mg, 1,608mg, 1,609mg, 1,610mg, 1,611mg, 1,612mg、1,613mg、1,614mg、1,615mg、1,616mg、1,617mg、1,618mg、1,619mg、1,620mg、1,621mg、1,622mg、1,623mg、1,624mg、1,625mg、1,626mg、1,627mg、1,628mg、1,629mg、1,630mg、1,631mg、1,632mg、1,633mg、1,634mg、1,635mg、1,636mg、1,637mg、1,638mg、1,639mg、1,640mg、1,641mg、1,642mg、1,643mg、1,644mg、1,645mg、1,646mg、1,647mg、1,648mg、1,649mg、1,650mg、1,651mg、1,652mg、1,653mg、1,654mg、1,655mg、1,656mg、1,657mg、1,658mg、1,659mg、1,660mg、1,661mg、1,662mg、1,663mg、1,664mg、1,665mg、1,666mg、1,667mg、1,668mg、1,669mg、1,670mg、1,671mg、1,672mg、1,673mg、1,674mg、1,675mg、1,676mg、1,677mg、1,678mg、1,679mg、1,680mg、1,681mg、1,682mg、1,683mg、1,684mg、1,685mg、1,686mg、1,687mg、1,688mg、1,689mg、1,690mg、1,691mg、1,692mg、1,693mg、1,694mg、1,695mg、1,696mg、1,697mg、1,698mg、1,699mg、1,700mg、1,701mg、1,702mg、1,703mg、1,704mg、1,705mg、1,706mg、1,707mg、1,708mg、1,709mg、1,710mg、1,711mg、1,712mg、1,713mg、1,714mg、1,715mg、1,716mg、1,717mg、1,718mg、1,719mg、1,720mg、1,721mg、1,722mg、1,723mg、1,724mg、1,725mg、1,726mg、1,727mg、1,728mg、1,729mg、1,730mg、1,731mg、1,732mg、1,733mg、1,734mg、1,735mg、1,736mg、1,737mg、1,738mg、1,739mg、1,740mg、1,741mg、1,742mg、1,743mg、1,744mg、1,745mg、1,746mg、1,747mg、1,748mg、1,749mg、1,750mg、1,751mg、1,752mg、1,753mg、1,754mg、1,755mg、1,756mg、1,757mg、1,758mg、1,759mg、1,760mg、1,761mg、1,762mg、1,763mg、1,764mg、1,765mg、1,766mg、1,767mg、1,768mg、1,769mg、1,770mg、1,771mg、1,772mg、1,773mg、1,774mg、1,775mg、1,776mg、1,777mg、1,778mg、1,779mg、1,780mg、1,781mg、1,782mg、1,783mg、1,784mg、1,785mg、1,786mg、1,787mg、1,788mg、1,789mg、1,790mg、1,791mg、1,792mg、1,793mg、1,794mg、1,795mg、1,796mg、1,797mg、1,798mg、1,799mg、1,800mg、1,801mg、1,802mg、1,803mg、1,804mg、1,805mg、1,806mg、1,807mg、1,808mg、1,809mg、1,810mg、1,811mg、1,812mg、1,813mg、1,814mg、1,815mg、1,816mg、1,817mg、1,818mg、1,819mg、1,820mg、1,821mg、1,822mg、1,823mg、1,824mg、1,825mg、1,826mg、1,827mg、1,828mg、1,829mg、1,830mg、1,831mg、1,832mg、1,833mg、1,834mg、1,835mg、1,836mg、1,837mg、1,838mg、1,839mg、1,840mg、1,841mg、1,842mg、1,843mg、1,844mg、1,845mg、1,846mg、1,847mg、1,848mg、1,849mg、1,850mg、1,851mg、1,852mg、1,853mg、1,854mg、1,855mg、1,856mg、1,857mg、1,858mg、1,859mg、1,860mg、1,861mg、1,862mg、1,863mg、1,864mg、1,865mg、1,866mg、1,867mg、1,868mg、1,869mg、 1,870mg、1,871mg、1,872mg、1,873mg、1,874mg、1,875mg、1,876mg、1,877mg 、1,878mg、1,879mg、1,880mg、1,881mg、1,882mg、1,883mg、1,884mg、1,885 mg、1,886mg、1,887mg、1,888mg、1,889mg、1,890mg、1,891mg、1,892mg、1.89 3mg、1,894mg、1,895mg、1,896mg、1,897mg、1,898mg、1,899mg、1,900mg、1, 901mg、1,902mg、1,903mg、1,904mg、1,905mg、1,906mg、1,907mg、1,908mg、1 ,909mg、1,910mg、1,911mg、1,912mg、1,913mg、1,914mg、1,915mg、1,916mg、1,917mg、1,918mg、1,919mg、1,920mg、1,921mg、1,922mg、1,923mg、1,924m g、1,925mg、1,926mg、1,927mg、1,928mg、1,929mg、1,930mg、1,931mg、1,932mg、1,933mg、1,934mg、1,935mg、1,936mg、1,937mg、1,938mg、1,939mg、1,9 40mg、1,941mg、1,942mg、1,943mg、1,944mg、1,945mg、1,946mg、1,947mg、1 ,948mg、1,949mg、1,950mg、1,951mg、1,952mg、1,953mg、1,954mg、1,955mg、 1,956mg、1,957mg、1,958mg、1,959mg、1,960mg、1,961mg、1,962mg、1,963mg、1,964mg、1,965mg、1,966mg、1,967mg、1,968mg、1,969mg、1,970mg、1,971 mg、1,972mg、1,973mg、1,974mg、1,975mg、1,976mg、1,977mg、1,978mg、1,979mg、1,980mg、1,981mg、1,982mg、1,983mg、1,984mg、1,985mg、1,986mg、1,987mg, 1,988mg, 1,989mg, 1,990mg, 1,991mg, 1,992mg, 1,993mg, 1,994mg, 1,995mg, 1,996mg, 1,997mg, 1,998mg, 1,999mg, 2,000mg, 2,001mg, 2,002m g, 2,003mg, 2,004mg, 2,005mg, 2,006mg, 2,007mg, 2,008mg, 2,009mg, 2,010mg, 2,011mg, 2,012mg, 2,013mg, 2,014mg, 2,015mg, 2,016mg, 2,017mg, 2,0 18mg, 2,019mg, 2,020mg, 2,021mg, 2,022mg, 2,023mg, 2,024mg, 2,025mg, 2,026mg, 2,027mg, 2,028mg, 2,029mg, 2,030mg, 2,031mg, 2,032mg, 2,033mg, 2,034mg, 2,035mg, 2,036mg, 2,037mg, 2,038mg, 2,039mg, 2,040mg, 2,041mg, 2,042mg, 2,043mg, 2,044mg, 2,045mg, 2,046mg, 2,047mg, 2,048mg, 2,049 mg, 2,050mg, 2,051mg, 2,052mg, 2,053mg, 2,054mg, 2,055mg, 2,056mg, 2,057mg, 2,058mg, 2,059mg, 2,060mg, 2,061mg, 2,062mg, 2,063mg, 2,064mg, 2 ,065mg, 2,066mg, 2,067mg, 2,068mg, 2,069mg, 2,070mg, 2,071mg, 2,072mg, 2,073mg, 2,074mg, 2,075mg, 2,076mg, 2,077mg, 2,078mg, 2,079mg, 2,080m g, 2,081 mg, 2,082 mg, 2,083 mg, 2,084 mg, 2,085 mg, 2,086 mg, 2,087 mg, 2,088 mg, 2,089 mg, 2,090 mg, 2,091 mg, 2,092 mg, 2,093 mg, 2,094 mg, 2,095 mg, 2,096 mg, 2,097 mg, 2,098 mg, or 2,099 mg in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) to a subject (e.g., an oxytocin antagonist represented by Formula (II) (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime).

[0209] For example, in some embodiments, the oxytocin antagonist is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,600 mg to about 2,000 mg, e.g., a total of about 1,600 mg, 1,601 mg, 1,602 mg, 1,603 mg, 1,604 mg, 1,605 mg, 1,606 mg, 1,607 mg, 1,608 mg, 1,609 mg, 1,610 mg, 1,611 mg, 1,612 mg, 1,613 mg, 1,614 mg, 1,615 mg, 1,616 mg, 1,617 mg, g, 1,618mg, 1,619mg, 1,620mg, 1,621mg, 1,622mg, 1,623mg, 1,624mg, 1,625mg, 1,626mg, 1,627mg, 1,628mg, 1,629mg, 1,630mg, 1,631mg, 1,632mg, 1, 633mg, 1,634mg, 1,635mg, 1,636mg, 1,637mg, 1,638mg, 1,639mg, 1,640mg, 1,641mg, 1,642mg, 1,643mg, 1,644mg, 1,645mg, 1,646mg, 1,647mg, 1,648mg , 1,649mg, 1,650mg, 1,651mg, 1,652mg, 1,653mg, 1,654mg, 1,655mg, 1,656mg, 1,657mg, 1,658mg, 1,659mg, 1,660mg, 1,661mg, 1,662mg, 1,663mg, 1,6 64mg, 1,665mg, 1,666mg, 1,667mg, 1,668mg, 1,669mg, 1,670mg, 1,671mg, 1,672mg, 1,673mg, 1,674mg, 1,675mg, 1,676mg, 1,677mg, 1,678mg, 1,679mg, 1,680mg, 1,681mg, 1,682mg, 1,683mg, 1,684mg, 1,685mg, 1,686mg, 1,687mg, 1,688mg, 1,689mg, 1,690mg, 1,691mg, 1,692mg, 1,693mg, 1,694mg, 1,695 mg, 1,696mg, 1,697mg, 1,698mg, 1,699mg, 1,700mg, 1,701mg, 1,702mg, 1,703mg, 1,704mg, 1,705mg, 1,706mg, 1,707mg, 1,708mg, 1,709mg, 1,710mg, 1,711mg、1,712mg、1,713mg、1,714mg、1,715mg、1,716mg、1,717mg、1,718mg、1,719mg、1,720mg、1,721mg、1,722mg、1,723mg、1,724mg、1,725mg、1,726mg 、1,727mg、1,728mg、1,729mg、1,730mg、1,731mg、1,732mg、1,733mg、1,734mg、1,735mg、1,736mg、1,737mg、1,738mg、1,739mg、1,740mg、1,741mg、1,74 2mg、1,743mg、1,744mg、1,745mg、1,746mg、1,747mg、1,748mg、1,749mg、1,750mg、1,751mg、1,752mg、1,753mg、1,754mg、1,755mg、1,756mg、1,757mg、1 ,758mg、1,759mg、1,760mg、1,761mg、1,762mg、1,763mg、1,764mg、1,765mg、1,766mg、1,767mg、1,768mg、1,769mg、1,770mg、1,771mg、1,772mg、1,773m g、1,774mg、1,775mg、1,776mg、1,777mg、1,778mg、1,779mg、1,780mg、1,781mg、1,782mg、1,783mg、1,784mg、1,785mg、1,786mg、1,787mg、1,788mg、1,7 89mg、1,790mg、1,791mg、1,792mg、1,793mg、1,794mg、1,795mg、1,796mg、1 ,797mg、1,798mg、1,799mg、1,800mg、1,801mg、1,802mg、1,803mg、1,804mg、 1,805mg、1,806mg、1,807mg、1,808mg、1,809mg、1,810mg、1,811mg、1,812m g、1,813mg、1,814mg、1,815mg、1,816mg、1,817mg、1,818mg、1,819mg、1,820 mg、1,821mg、1,822mg、1,823mg、1,824mg、1,825mg、1,826mg、1,827mg、1,8 28mg、1,829mg、1,830mg、1,831mg、1,832mg、1,833mg、1,834mg、1,835mg、1,836mg、1,837mg、1,838mg、1,839mg、1,840mg、1,841mg、1,842mg、1,843mg、1,844mg、1,845mg、1,846mg、1,847mg、1,848mg、1,849mg、1,850mg、1,851mg、1,852mg、1,853mg、1,854mg、1,855mg、1,856mg、1,857mg、1,858mg、1,859mg、1,860mg、1,861mg、1,862mg、1,863mg、1,864mg、1,865mg、1,866mg、1,867mg、1,868mg、1,869mg、1,870mg、1,871mg、1,872mg、1,873mg、1,874mg、1,875mg、1,876mg、1,877mg、1,878mg、1,879mg、1,880mg、1,881mg、1,882mg、1,883mg、1,884mg、1,885mg、1,886mg、1,887mg、1,888mg、1,889mg、1,890mg、1,891mg、1,892mg、1,893mg、1,894mg、1,895mg、1,896mg、1,897mg、1,898mg、1,899mg、1,900mg、1,901mg、1,902mg、1,903mg、1,904mg、1,905mg、1,906mg、1,907mg、1,908mg、1,909mg、1,910mg、1,911mg、1,912mg、1,913mg、1,914mg、1,915mg、1,916mg、1,917mg、1,918mg、1,919mg、1,920mg、1,921mg、1,922mg、1,923mg、1,924mg、1,925mg、1,926mg、1,927mg、1,928mg、1,929mg、1,930mg、1,931mg、1,932mg、1,933mg、1,934mg、1,935mg、1,936mg、1,937mg、1,938mg、1,939mg、1,940mg、1,941mg、1,942mg、1,943mg、1,944mg、1,945mg、1,946mg、1,947mg、1,948mg、1,949mg、1,950mg、1,951mg、1,952mg、1,953mg、1,954mg、1,955mg、1,956mg、1,957mg、1,958mg、1,959mg、1,960mg、1,961mg, 1,962mg, 1,963mg, 1,964mg, 1,965mg, 1,966mg, 1,967mg, 1,968mg, 1,969mg, 1,970mg, 1,971mg, 1,972mg, 1,973mg, 1,974mg, 1,975mg, 1,97 6mg, 1,977mg, 1,978mg, 1,979mg, 1,980mg, 1,981mg, 1,982mg, 1,983mg, 1,984mg, 1,985mg, 1,986mg, 1,987mg, 1,988mg, 1,989mg, 1,990mg, 1,991m The oxytocin antagonist is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of 1,992 mg, 1,993 mg, 1,994 mg, 1,995 mg, 1,996 mg, 1,997 mg, 1,998 mg, 1,999 mg, or 2,000 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0210] For example, in some embodiments, the oxytocin antagonist is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,700 mg to about 1,900 mg, e.g., about 1,700 mg, 1,701 mg, 1,702 mg, 1,703 mg, 1,704 mg, 1,705 mg, 1,706 mg, 1,707 mg, 1,708 mg, 1,709 mg, 1,710 mg, 1,711 mg, 1,712 mg, 1,713 mg, 1,714 mg, 1,715 mg, 1,716 mg, 1,717 mg , 1,718mg, 1,719mg, 1,720mg, 1,721mg, 1,722mg, 1,723mg, 1,724mg, 1,725mg, 1,726mg, 1,727mg, 1,728mg, 1,729mg, 1,730mg, 1,731mg, 1,732mg, 1,7 33mg, 1,734mg, 1,735mg, 1,736mg, 1,737mg, 1,738mg, 1,739mg, 1,740mg, 1,741mg, 1,742mg, 1,743mg, 1,744mg, 1,745mg, 1,746mg, 1,747mg, 1,748mg, 1,749mg, 1,750mg, 1,751mg, 1,752mg, 1,753mg, 1,754mg, 1,755mg, 1,756mg, 1,757mg, 1,758mg, 1,759mg, 1,760mg, 1,761mg, 1,762mg, 1,763mg, 1,76 4mg, 1,765mg, 1,766mg, 1,767mg, 1,768mg, 1,769mg, 1,770mg, 1,771mg, 1,772mg, 1,773mg, 1,774mg, 1,775mg, 1,776mg, 1,777mg, 1,778mg, 1,779mg, 1 ,780mg, 1,781mg, 1,782mg, 1,783mg, 1,784mg, 1,785mg, 1,786mg, 1,787mg, 1,788mg, 1,789mg, 1,790mg, 1,791mg, 1,792mg, 1,793mg, 1,794mg, 1,795 mg, 1,796mg, 1,797mg, 1,798mg, 1,799mg, 1,800mg, 1,801mg, 1,802mg, 1,803mg, 1,804mg, 1,805mg, 1,806mg, 1,807mg, 1,808mg, 1,809mg, 1,810mg, 1,811mg, 1,812mg, 1,813mg, 1,814mg, 1,815mg, 1,816mg, 1,817mg, 1,818mg, 1,819mg, 1,820mg, 1,821mg, 1,822mg, 1,823mg, 1,824mg, 1 ,825mg, 1,826mg, 1,827mg, 1,828mg, 1,829mg, 1,830mg, 1,831mg, 1,832mg, 1,833mg, 1,834mg, 1,835mg, 1,836mg, 1,837mg, 1,838mg, 1,839mg, 1,840mg, 1,841mg, 1,842mg, 1,843mg, 1,844mg, 1,845mg, 1,846mg, 1,847mg, 1,848mg, 1,849mg, 1,850mg, 1,851mg, 1,852mg , 1,853mg, 1,854mg, 1,855mg, 1,856mg, 1,857mg, 1,858mg, 1,859mg, 1,860mg, 1,861mg, 1,862mg, 1,863mg, 1,864mg, 1,865mg, 1,866m g, 1,867mg, 1,868mg, 1,869mg, 1,870mg, 1,871mg, 1,872mg, 1,873mg, 1,874mg, 1,875mg, 1,876mg, 1,877mg, 1,878mg, 1,879mg, 1,880 mg, 1,881mg, 1,882mg, 1,883mg, 1,884mg, 1,885mg, 1,886mg, 1,887mg, 1,888mg, 1,889mg, 1,890mg, 1,891mg, 1,892mg, 1,893mg, 1,89 The oxytocin antagonist is administered to a subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of 4 mg, 1,895 mg, 1,896 mg, 1,897 mg, 1,898 mg, 1,899 mg, or 1,900 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0211] For example, in some embodiments, the oxytocin antagonist is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,750 mg to about 1,850 mg, e.g., about 1,750 mg, 1,751 mg, 1,752 mg, 1,753 mg, 1,754 mg, 1,755 mg, 1,756 mg, 1,757 mg, 1,758 mg, 1,759 mg, 1,760 mg, 1,761 mg, 1,762 mg, 1,763 mg, 1,764 mg, 1,765 mg, 1,766 mg, 1,767 mg, 1,768mg, 1,769mg, 1,770mg, 1,771mg, 1,772mg, 1,773mg, 1,774mg, 1,775mg, 1,776mg, 1,777mg, 1,778mg, 1,779mg, 1,780mg, 1,781mg, 1,782mg, 1,78 3mg, 1,784mg, 1,785mg, 1,786mg, 1,787mg, 1,788mg, 1,789mg, 1,790mg, 1,791mg, 1,792mg, 1,793mg, 1,794mg, 1,795mg, 1,796mg, 1,797mg, 1,798mg, 1,799mg, 1,800mg, 1,801mg, 1,802mg, 1,803mg, 1,804mg, 1,805mg, 1,806mg, 1,807mg, 1,808mg, 1,809mg, 1,810mg, 1,811mg, 1,812mg, 1,813mg, 1,81 4mg, 1,815mg, 1,816mg, 1,817mg, 1,818mg, 1,819mg, 1,820mg, 1,821mg, 1,822mg, 1,823mg, 1,824mg, 1,825mg, 1,826mg, 1,827mg, 1,828mg, 1,829mg, The oxytocin antagonist is administered to the subject in an amount of 1,830 mg, 1,831 mg, 1,832 mg, 1,833 mg, 1,834 mg, 1,835 mg, 1,836 mg, 1,837 mg, 1,838 mg, 1,839 mg, 1,840 mg, 1,841 mg, 1,842 mg, 1,843 mg, 1,844 mg, 1,845 mg, 1,846 mg, 1,847 mg, 1,848 mg, 1,849 mg, or 1,850 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime).

[0212] For example, in some embodiments, the oxytocin antagonist is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,760 mg to about 1,840 mg, e.g., a total of about 1,760 mg, 1,761 mg, 1,762 mg, 1,763 mg, 1,764 mg, 1,765 mg, 1,766 mg, 1,767 mg, 1,768 mg, 1,769 mg, 1,770 mg, 1,771 mg, 1,772 mg, 1,773 mg, 1,774 mg, 1,775 mg, 1,776 mg, 1,776mg, 1,777mg, 1,778mg, 1,779mg, 1,780mg, 1,781mg, 1,782mg, 1,783mg, 1,784mg, 1,785mg, 1,786mg, 1,787mg, 1,788mg, 1,789mg, 1,790mg, 1,791mg, 1,792mg, 1,793mg, 1,794mg, 1,795mg, 1,796mg, 1,797mg, 1,798mg, 1,799mg, 1,800mg, 1,801mg, 1,802mg, 1,803mg, 1,80 4mg, 1,805mg, 1,806mg, 1,807mg, 1,808mg, 1,809mg, 1,810mg, 1,811mg, 1,812mg, 1,813mg, 1,814mg, 1,815mg, 1,816mg, 1,817mg, 1,818mg , 1,819mg, 1,820mg, 1,821mg, 1,822mg, 1,823mg, 1,824mg, 1,825mg, 1,826mg, 1,827mg, 1,828mg, 1,829mg, 1,830mg, 1,831mg, 1,832mg, 1,8 The oxytocin antagonist is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of 33 mg, 1,834 mg, 1,835 mg, 1,836 mg, 1,837 mg, 1,838 mg, 1,839 mg, or 1,840 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0213] For example, in some embodiments, the oxytocin antagonist is administered in one or more doses totaling about 1,770 mg to about 1,830 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), e.g., about 1,770 mg, 1,771 mg, 1,772 mg, 1,773 mg, 1,774 mg, 1,775 mg, 1,776 mg, 1,777 mg, 1,778 mg, 1,779 mg, 1,780 mg, 1,781 mg, 1,782 mg, 1,783 mg, 1,784 mg, 1,785 mg, 1,786 mg, 1,787 mg, 1,788 mg, 1,789 mg, 1,790 mg, 1,791 mg, 1,792 mg, 1,793 mg, 1,794 mg, 1,795 mg, 1,796 mg, 1,797 mg, 1,798 mg, 1,799 mg, 1,800 mg, 1,801 mg, 1,802 mg, 1,803 mg, 1,804 mg, 1,805 mg, 1,806 mg, 1,807 mg, 1,808 mg, 1,809 mg, 1,810 mg, 1,811 mg, 1,812 mg, 1,813 mg, 1,814 mg, 1,815 mg, 1,816 mg, 1,817 mg, 1,818 mg, 1,819 mg, 1,820 mg, 1,821 mg, 1,822 mg, 79mg, 1,780mg, 1,781mg, 1,782mg, 1,783mg, 1,784mg, 1,785mg, 1,786mg, 1,787mg, 1,788mg, 1,789mg, 1,79 0mg, 1,791mg, 1,792mg, 1,793mg, 1,794mg, 1,795mg, 1,796mg, 1,797mg, 1,798mg, 1,799mg, 1,800mg, 1,801m g, 1,802mg, 1,803mg, 1,804mg, 1,805mg, 1,806mg, 1,807mg, 1,808mg, 1,809mg, 1,810mg, 1,811mg, 1,812mg , 1,813mg, 1,814mg, 1,815mg, 1,816mg, 1,817mg, 1,818mg, 1,819mg, 1,820mg, 1,821mg, 1,822mg, 1,823mg, 1 The oxytocin antagonist is administered to a subject in an amount of 1,824 mg, 1,825 mg, 1,826 mg, 1,827 mg, 1,828 mg, 1,829 mg, or 1,830 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0214] For example, in some embodiments, the oxytocin antagonist is administered in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) totaling about 1,780 mg to about 1,820 mg, e.g., about 1,780 mg, 1,781 mg, 1,782 mg, 1,783 mg, 1,784 mg, 1,785 mg, 1,786 mg, 1,787 mg, 1,788 mg, 1,789 mg, 1,790 mg, 1,791 mg, 1,792 mg, 1,793 mg, 1,794 mg, 1,795 mg, 1,796 mg, 1,797 mg, 1,798 mg, 1,799 mg, 1,800 mg, 1,801 mg g, 1,802 mg, 1,803 mg, 1,804 mg, 1,805 mg, 1,806 mg, 1,807 mg, 1,808 mg, 1,809 mg, 1,810 mg, 1,811 mg, 1,812 mg, 1,813 mg, 1,814 mg, 1,815 mg, 1,816 mg, 1,817 mg, 1,818 mg, 1,819 mg, or 1,820 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0215] For example, in some embodiments, the oxytocin antagonist is administered in one or more doses totaling about 1,790 mg to about 1,810 mg (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses), e.g., about 1,790 mg, 1,791 mg, 1,792 mg, 1,793 mg, 1,794 mg, 1,795 mg, 1,796 mg, 1,797 mg, 1,798 mg, 1,799 mg, 1,800 mg, 1,801 mg g, 1,802 mg, 1,803 mg, 1,804 mg, 1,805 mg, 1,806 mg, 1,807 mg, 1,808 mg, 1,809 mg, or 1,810 mg (e.g., the oxytocin antagonist is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime represented by formula (II)).

[0216] In some embodiments, the compound is administered in a total amount of about 2,100 mg to about 2,700 mg, about 2,150 mg to about 2,650 mg, about 2,200 mg to about 2,600 mg, about 2,250 mg to about 2,550 mg, about 2,300 mg to about 2,500 mg, about 2,350 mg to about 2,450 mg, about 2,360 mg to about 2,440 mg, about 2,370 mg to about 2,430 mg, about 2,380 mg to about 2,420 mg, about 2,390 mg to about 2,410 mg, about 2,391 mg to about 2,409 mg, about 2,392 mg to about 2,408 mg, about 2,393 mg to about 2,407 mg, about 2,394 mg The compound is administered to the subject in one or more doses (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) of about 2,406 mg, about 2,395 mg, about 2,405 mg, about 2,396 mg, about 2,404 mg, about 2,397 mg, about 2,403 mg, about 2,398 mg, about 2,402 mg, or about 2,399 mg, about 2,401 mg (e.g., the compound is (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbony...

Claims

[Claim 1] The compound represented by formula (II) includes (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, A pharmaceutical composition for use in a method of treating a subject undergoing embryo transfer therapy in which one or more embryos are transferred to the subject's uterus, said method comprising administering to said subject said compound in an amount of about 1,800 mg.

Images